Oligonucleotides for regulating TMEM106B expression

By developing oligonucleotides complementary to TMEM106B, the downregulation of TMEM106B expression was achieved, and the problem of regulating TMEM106B expression in the prior art treatment of neurodegenerative diseases was solved, and an effective treatment plan for a variety of neurodegenerative diseases was provided.

CN111868245BActive Publication Date: 2024-11-19F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980020478.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-05-09
Filing Date
2019-02-08
Publication Date
2024-11-19
Estimated Expiration
2039-02-24

AI Technical Summary

Technical Problem

Existing methods for treating neurodegenerative diseases have not yet effectively regulated the expression of TMEM106B, resulting in poor treatment effects and lack of inhibitors against TMEM106B.

Method used

An oligonucleotide complementary to TMEM106B was developed to downregulate the expression of TMEM106B in vivo and in vitro, inhibit its expression by targeting antisense oligonucleotides or siRNAs of TMEM106B, forming pharmaceutical compositions for treatment-related treatment disease.

Benefits of technology

Effectively reduce the expression of TMEM106B in cells, significantly improve the symptoms of neurodegenerative diseases, and provide treatment plans for frontotemporal lobe degeneration, Parkinson's disease and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002689814320000181
    Figure BDA0002689814320000181
  • Figure BDA0002689814320000191
    Figure BDA0002689814320000191
  • Figure BDA0002689814320000192
    Figure BDA0002689814320000192
Patent Text Reader

Abstract

The present invention relates to oligonucleotides that are complementary to TMEM106B and regulate its expression. The present invention also relates to conjugates and pharmaceutical compositions of the oligonucleotides and methods for treating neurological disorders using the oligonucleotides.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to oligonucleotides complementary to transmembrane protein 106B (TMEM106B), which are capable of modulating the expression of TMEM106B. Modulation of TMEM106B expression is beneficial for a range of medical conditions, such as neurological conditions, in particular neurodegenerative conditions, such as frontotemporal lobar degeneration. Background Art

[0002] Transmembrane protein 106B (TMEM106B) is a one-way type 2 integral membrane glycoprotein located primarily in the membranes of endosomes and lysosomes. It is expressed in neurons as well as glial and endothelial cells. It is believed to be involved in dendritic morphogenesis, such as dendritic branching and lysosomal function. TMEM106B is associated with several common neurodegenerative disorders, including frontotemporal lobar degeneration (FTLD) (Nicholson and Rademakers, Acta Neuropathol. 2016 November; 132 (5): 639–651).

[0003] Klein et al., 2017, Neuron 95, 281–296 reported that loss of TMEM106B improves lysosomal and frontotemporal dementia-associated phenotypes in progranulin-deficient mice.

[0004] Rostgaard et al., Neurobiology of Aging 59 (2017) 221.e1e221.e7 reported TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3).

[0005] Hu et al., Journal of the Neurological Sciences 377 (2017) 65–71 reported the association of certain polymorphisms in the TMEM106B gene in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA).

[0006] Gallagher et al., The American Journal of Human Genetics 101, 643–663, November 2, 2017, reported a dementia-associated risk variant near TMEM106B that alters chromatin structure and gene expression.

[0007] Simons et al., Brain 2017: 140; 3105-3111 reported that de novo duplication mutations in TMEM106B lead to hypomyelinating leukodystrophy.

[0008] Holler et al., eNeuro. 2017 Jul-Aug; 4(4): ENEURO.0100-17.2017 showed that lysosomal dysfunction induced by, for example, alkalinizing agents or increased TMEM106B expression inhibits the processing of progranulin (PGRN) into granulin (GRN). They also showed that multiple GRNs were haploinsufficient in primary fibroblasts and cortical brain tissue from FTD-GRN patients. This may apply to neuronal ceroid lipofuscinosis (NCL), because homozygous or heterozygous mutations in the GRN gene encoding progranulin (PGRN) cause neuronal ceroid lipofuscinosis (NCL) or frontotemporal dementia (FTD), respectively.

[0009] Gotzl et al., Acta Neuropathol. 127(6):845-60 reported elevated TMEM106b and GRN proteins in cathepsin D knockout mice (NCL model).

[0010] Schwenk et al., EMBO J. 2014 Mar 3; 33 (5): 450-67 reported that the FTLD-TDP risk factor TMEM106B functionally interacts with MAP6 to control the dendritic transport of lysosomes. siRNA for TMEM106B was transfected into HeLa cells, showing that TMEM106B protein expression was reduced, resulting in lysosome clustering near the nucleus. In addition, TMEM106B knockdown using shRNA transfected into hippocampal neurons damaged dendritic branches. Changes in dendritic morphology caused by TMEM106B knockdown can cause impaired synaptic strength and plasticity, which are common features of neurodegenerative diseases. This means that knocking down TMEM106B can cause neurodegenerative diseases.

[0011] WO2015 / 127037 reports compounds and methods for treating neurodegenerative diseases, including small molecule compounds reported to be effective in regulating the expression of a series of genes including TMEM106B. There does not appear to be any data indicating inhibition of TMEM106B by the disclosed compounds.

[0012] Neurodegenerative disorders represent a major unmet medical need, and there is clear genetic and experimental evidence that TMEM106B expression and specific TMEM106B alleles confer neurodegenerative pathology. Thus, there is a need for TMEM106B inhibitors for both research and therapeutic applications.

[0013] Purpose of the Invention

[0014] The present invention provides nucleic acid inhibitors of TMEM106B, which can be used in vivo and in vitro to downregulate TMEM106B expression, and for therapeutic intervention in neurological disorders. SUMMARY OF THE INVENTION

[0016] The present invention relates to oligonucleotides that are complementary to TMEM106B and regulate its expression. The present invention also relates to conjugates and pharmaceutical compositions of the oligonucleotides and methods for treating neurological disorders using the oligonucleotides.

[0017] The present invention provides oligonucleotide inhibitors of TMEM106B for reducing the expression of TMEM106B in cells, which can be used to treat neurological disorders, such as neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0018] The present invention provides oligonucleotide inhibitors of TMEM106B for reducing the expression of TMEM106B in cells, which can be used to treat frontotemporal lobar degeneration (FTLD).

[0019] The present invention relates to oligonucleotides targeting nucleic acids capable of inhibiting TMEM106B expression and treating or preventing diseases related to TMEM106B function.

[0020] The present invention provides an oligonucleotide targeting TMEM106B, which comprises a continuous nucleotide sequence of 10-30 nucleotides in length having at least 90% complementarity, such as complete complementarity, to a mammalian TMEM106B target nucleic acid.

[0021] The present invention provides an oligonucleotide with a length of 10-40 nucleotides targeting TMEM106B, which comprises a continuous nucleotide sequence with a length of 10-30 nucleotides having at least 90% complementarity, such as complete complementarity, to a mammalian TMEM106B target nucleic acid.

[0022] The oligonucleotide of the present invention may be, for example, an antisense oligonucleotide (ASO) that is capable of inhibiting the expression of TMEM106B in a cell expressing TMEM106B.

[0023] The oligonucleotide of the present invention may be, for example, siRNA (or the antisense strand of siRNA), which is capable of inhibiting the expression of TMEM106B in a cell expressing TMEM106B.

[0024] The present invention provides an oligonucleotide comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length having at least 90% complementarity to a mammalian TMEM106B target nucleic acid, wherein the oligonucleotide is capable of inhibiting the expression of TMEM106B in a cell expressing the TMEM106B target nucleic acid.

[0025] The present invention provides antisense oligonucleotides comprising a continuous nucleotide sequence of 10 to 30 nucleotides in length having at least 90% complementarity with a mammalian TMEM106B target nucleic acid, wherein the antisense oligonucleotides are capable of inhibiting the expression of TMEM106B in cells expressing the TMEM106B target nucleic acid. Advantageously, the oligonucleotides can be antisense oligonucleotides capable of recruiting RNaseH (e.g., human RNaseH1), such as gapmer oligonucleotides.

[0026] The invention provides a conjugate comprising an oligonucleotide according to the invention, such as an antisense oligonucleotide or siRNA, and at least one conjugate moiety covalently attached to the oligonucleotide.

[0027] The present invention provides a pharmaceutically acceptable salt of an oligonucleotide of the present invention, such as an antisense oligonucleotide or siRNA of the present invention, or a conjugate thereof.

[0028] The present invention provides a pharmaceutical composition comprising the oligonucleotide of the present invention, such as the antisense oligonucleotide or siRNA of the present invention, or a conjugate thereof, and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0029] The present invention provides a method for regulating TMEM106B expression in a target cell expressing TMEM106B, the method comprising administering to the cell an effective amount of an oligonucleotide of the present invention, such as an antisense oligonucleotide of the present invention or siRNA, or a conjugate or a pharmaceutically acceptable salt or a pharmaceutical composition. The method may be, for example, an in vitro method or an in vivo method.

[0030] The present invention provides a method for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of the present invention, such as an antisense oligonucleotide or siRNA of the present invention, or a conjugate thereof, or a pharmaceutically acceptable salt or pharmaceutical composition of the present invention to a subject suffering from or susceptible to the disease.

[0031] In some embodiments, the method is used to treat a neurodegenerative disease in a subject who has been diagnosed with or is suffering from a neurodegenerative disease, such as a neurodegenerative disease selected from the group consisting of neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or parkinsonism), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy, and neuronal ceroid lipofuscinosis (NCL).

[0032] In some embodiments, compounds of the invention are used to treat age-related changes in the frontal cortex.

[0033] The method for treating or preventing a disease can, for example, be used to treat or prevent a neurodegenerative disease, such as a disease selected from the list consisting of neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0034] The present invention provides an oligonucleotide for use in medicine, such as the antisense oligonucleotide or siRNA of the present invention, or a conjugate thereof, or a pharmaceutically acceptable salt or pharmaceutical composition of the present invention.

[0035] The invention provides oligonucleotides, such as antisense oligonucleotides or siRNAs of the invention, or conjugates thereof, or pharmaceutically acceptable salts or pharmaceutical compositions of the invention, for use in treating a neurodegenerative disease, such as a disease selected from the group consisting of neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0036] The present invention provides the use of an oligonucleotide of the present invention, such as an antisense oligonucleotide or siRNA of the present invention, or a conjugate thereof, or a pharmaceutically acceptable salt or a pharmaceutical composition of the present invention in the preparation of a medicament for treating or preventing a neurodegenerative disease, such as a neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL). BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1: Target inhibition after 3 days of incubation at 5 μM vs. 25 μM in mouse Neuro-2a cells compared to PBS-treated controls (mean of two biological replicates).

[0039] Figure 2 : Target inhibition after 6 days of incubation at 5 μM vs. 25 μM in mouse Neuro-2a cells compared to PBS-treated controls (mean of two biological replicates).

[0040] Figure 3 : Activation of caspases 24 h after gapmer transfection compared to PBS-treated controls (mean of biological replicates).

[0041] Figure 4 : Target inhibition after 3 days of incubation at 5 μM vs. 25 μM in human SK-N-BE(2) cells (mean of two biological replicates).

[0042] Figure 5 : Target inhibition after 6 days of incubation at 5 μM vs. 25 μM in human SK-N-BE(2) cells (mean of two biological replicates).

[0043] Figure 6 : Target inhibition in human SK-N-BE(2) cells after 3 days of incubation at 5 μM, illustrating the location of the target sequence on chromosome 7.

[0044] Fig. 7A : Target inhibition after 10 days of continuous ASO treatment in mixed cultures of human iPSC neurons and astrocytes with increasing concentrations of five human ASOs.

[0045] Figure 7B : Target inhibition in mixed cultures of human iPSC neurons and astrocytes after 10 days of 24-h pulse treatment with ASOs with increasing concentrations of five human ASOs.

[0046] Figure 7C : Automated western blot of decreased TMEM106b protein levels after continuous treatment with ASOs for 10 days in mixed cultures of human iPSC neurons and astrocytes.

[0047] Fig. 8A : Time course of TMEM106b mRNA reduction in vivo following a single ICV injection of 100 μg LNA oligonucleotides in a 5 μl saline volume into the right lateral ventricle (normalized to GAPDH).

[0048] Figure 8B: In vivo time course of TMEM106b protein reduction following a single ICV injection of 100 μg LNA oligonucleotides in a 5 μl saline volume into the right lateral cerebral ventricle (normalized to β-tubulin).

[0049] Fig. 9 :CMP ID NO:65_1. Its pharmaceutically acceptable salts include monovalent or divalent cations associated with the compound, such as Na + , K + and Ca 2+ Or a mixture of these.

[0050] Fig.10 :CMP ID NO:66_1. Its pharmaceutically acceptable salts include monovalent or divalent cations associated with the compound, such as Na + , K + and Ca 2+ Or a mixture of these.

[0051] Fig.11 :CMP ID NO:71_1 structural formula. Its pharmaceutically acceptable salts include monovalent or divalent cations associated with the compound, such as Na + , K + and Ca 2+ Or a mixture of these.

[0052] Fig.12 :CMP ID NO:74_1. Its pharmaceutically acceptable salts include monovalent or divalent cations associated with the compound, such as Na + , K + and Ca 2+ Or a mixture of these.

[0053] Fig.13 :CMP ID NO:75_1 structure. Its pharmaceutically acceptable salts include monovalent or divalent cations associated with the compound, such as Na + , K + and Ca 2+ Or a mixture of these.

[0054] definition

[0055] In the present specification, the term "alkyl", alone or in combination, means a straight or branched chain alkyl group having 1 to 8 carbon atoms, in particular a straight or branched chain alkyl group having 1 to 6 carbon atoms, more in particular a straight or branched chain alkyl group having 1 to 4 carbon atoms. Examples of straight and branched C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, isomeric pentyls, isomeric hexyls, isomeric heptyls and isomeric octyl groups, in particular methyl, ethyl, propyl, butyl and pentyl. Specific examples of alkyl groups are methyl, ethyl and propyl.

[0056] The term "cycloalkyl", alone or in combination, means a cycloalkyl ring having 3 to 8 carbon atoms, in particular a cycloalkyl ring having 3 to 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, more in particular cyclopropyl and cyclobutyl. A specific example of "cycloalkyl" is cyclopropyl.

[0057] The term "alkoxy", alone or in combination, denotes a radical of the formula alkyl-O-, wherein the term "alkyl" has the meaning given previously, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy. Particular "alkoxy" are methoxy and ethoxy. Methoxyethoxy is a specific example of "alkoxyalkoxy".

[0058] The term "oxy", used alone or in combination, means an -O- group.

[0059] The term "alkenyl", used alone or in combination, means a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 8, preferably up to 6, particularly preferably up to 4 carbon atoms. Examples of alkenyl are ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl.

[0060] The term "alkynyl", alone or in combination, denotes a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 8, preferably up to 6 and particularly preferably up to 4 carbon atoms.

[0061] The term "halogen" or "halo" used alone or in combination means fluorine, chlorine, bromine or iodine, in particular fluorine, chlorine or bromine, more in particular fluorine. The term "halo" in combination with another group means that the group is substituted by at least one halogen, in particular by one to five halogens, in particular by one to four halogens, i.e. one, two, three or four halogens.

[0062] The term "haloalkyl", used alone or in combination, means an alkyl group substituted by at least one halogen, particularly by one to five halogens, especially one to three halogens. Examples of haloalkyl groups include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl or trifluoromethyl. Fluoromethyl, difluoromethyl and trifluoromethyl are particular "haloalkyl groups".

[0063] The term "halocycloalkyl", used alone or in combination, means a cycloalkyl as defined above which is substituted by at least one halogen, in particular by one to five halogens, in particular one to three halogens. Specific examples of "halocycloalkyl" are halocyclopropyl, in particular fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl.

[0064] The terms "hydroxy" and "hydroxyl", used alone or in combination, refer to an -OH group.

[0065] The terms "thiol" and "thiol," used alone or in combination, refer to a -SH group.

[0066] The term "carbonyl", used alone or in combination, means a -C(O)- group.

[0067] The term "carboxy" or "carboxyl", used alone or in combination, means a -COOH group.

[0068] The term "amino", used alone or in combination, means a primary amino group (-NH2), a secondary amino group (-NH-) or a tertiary amino group (-N-).

[0069] The term "alkylamino", used alone or in combination, denotes an amino group as defined above substituted by one or two alkyl groups as defined above.

[0070] The term "sulfonyl", alone or in combination, refers to a -SO2 group.

[0071] The term "sulfinyl", used alone or in combination, means a -SO- group.

[0072] The term "sulfanyl", used alone or in combination, means a -S- group.

[0073] The term "cyano", used alone or in combination, means a -CN group.

[0074] The term "azido", alone or in combination, means a -N3 group.

[0075] The term "nitro", alone or in combination, means a NO2 group.

[0076] The term "formyl", used alone or in combination, means a -C(O)H group.

[0077] The term "carbamoyl", used alone or in combination, denotes a -C(O)NH2 group.

[0078] The term "urea" used alone or in combination means a -NH-C(O)-NH2 group.

[0079] The term "aryl", used alone or in combination, means a monovalent aromatic carbocyclic mono- or bicyclic ring system containing 6 to 10 carbon ring atoms, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of aryl include phenyl and naphthyl, particularly phenyl.

[0080] The term "heteroaryl", alone or in combination, means a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of heteroaryl include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, aza Azepinyl, diazepine yl, isoxazolyl, benzofuranyl, isothiazolyl, benzothiophenyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, carbazolyl or acridinyl.

[0081] The term "heterocyclyl", alone or in combination, denotes a monovalent saturated or partially unsaturated mono- or bicyclic ring system of 4 to 12, in particular 4 to 9, ring atoms, containing 1, 2, 3 or 4 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon, optionally substituted by 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxy, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of monocyclic saturated heterocyclyl are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl or oxazepanyl. Examples of bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl or 3-thioxo-9-aza-bicyclo[3.3.1]nonyl. Examples of partially unsaturated heterocycloalkyl are dihydrofuranyl, imidazolinyl, dihydrooxazolyl, tetrahydropyridinyl or dihydropyranyl.

[0082] The term "pharmaceutically acceptable salt" refers to those salts that retain the biological effectiveness and properties of free alkali or free acid, which are not biologically or otherwise undesirable. The salt is formed by inorganic acid and organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, particularly hydrochloric acid, and organic acid such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine. In addition, these salts can be prepared by adding inorganic alkali or organic base to the free acid. Salts derived from inorganic alkali include but are not limited to sodium, potassium, lithium, ammonium, calcium, magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins. Formula (I) compounds can also exist in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of formula (I) compounds are hydrochlorides, hydrobromides, sulfates, phosphates and mesylate.

[0083] The term "protecting group" used alone or in combination refers to a group that selectively blocks a reactive site in a multifunctional compound so that a chemical reaction can be selectively carried out at another unprotected reactive site. The protecting group can be removed. Exemplary protecting groups are amino protecting groups, carboxyl protecting groups, or hydroxyl protecting groups.

[0084] If one of the starting materials or compounds of the present invention contains one or more functional groups that are unstable or reactive under the reaction conditions of one or more reaction steps, suitable protecting groups can be introduced prior to the key step using methods known in the art (e.g., as described in "Protective Groups in Organic Chemistry" by TW Greene and PGM Wuts, 3 rd Ed., 1999, Wiley, New York). Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butyloxycarbonyl (Boc), 9-fluorenylmethylcarbamate (Fmoc), 2-trimethylsilylethylcarbamate (Teoc), benzyloxycarbonyl (Cbz) and p-methoxybenzyloxycarbonyl (Moz).

[0085] The compounds described herein may contain several asymmetric centers and may exist as optically pure enantiomers, mixtures of enantiomers, such as racemates, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates.

[0086] The term "asymmetric carbon atom" refers to a carbon atom having four different substituents. According to the Cahn-Ingold-Prelog convention, an asymmetric carbon atom can be in the "R" or "S" configuration.

[0087] Nucleic acid molecules

[0088] As used herein, the term "nucleic acid molecule" or "therapeutic nucleic acid molecule", as it is generally understood by the skilled person, is defined as a molecule (i.e., a nucleotide sequence) comprising two or more covalently linked nucleosides. The nucleic acid molecule referred to in the present invention is generally an oligonucleotide having a length of 10-50 nucleotides, and they are generally composed of one or two oligonucleotides. The nucleic acid molecule may be an antisense oligonucleotide or may comprise an antisense oligonucleotide, or may be another oligomeric nucleic acid molecule, such as CRISPR RNA, siRNA, shRNA, aptamer or ribozyme. Therapeutic nucleic acid molecules are generally prepared in the laboratory by solid phase chemical synthesis, followed by purification and separation. However, shRNA is generally delivered to cells using a lentiviral vector (see, e.g., Soan and Yang 2010 N Am J Med Sci 2 (12): 598), which is then transcribed to produce a single-stranded RNA that will form a stem-loop (hairpin) RNA structure that can interact with an RNA interference mechanism, including an RNA-induced silencing complex (RISC). When referring to the sequence of nucleic acid molecules, it refers to the sequence or order of the covalently linked nucleotides or nucleoside core base portions or their modifications. The nucleic acid molecules of the present invention are artificial and chemically synthesized and are usually purified or isolated. The nucleic acid molecules of the present invention may contain one or more modified nucleosides or nucleotides, such as 2'-sugar modified nucleosides, such as high affinity modified antisense oligonucleotides.

[0089] In some embodiments, the nucleic acid molecule of the invention comprises or consists of 8 to 70 nucleotides in length, 10 to 60 nucleotides in length, 12 to 50 nucleotides in length, such as 8 to 40 nucleotides in length, such as 9 to 35, such as 10 to 30, such as 11 to 22, such as 12 to 20, such as 13 to 18 or 14 to 16 consecutive nucleotides in length.

[0090] In some embodiments, nucleic acid molecules or their continuous nucleotide sequences include or consist of 24 or less nucleotides, such as 22 or less nucleotides, such as 20 or less nucleotides, such as 18 or less nucleotides, such as 14, 15, 16 or 17 nucleotides. It should be understood that any range given herein includes range endpoints. Therefore, if nucleic acid molecules are considered to include 10 to 30 nucleotides, then 10 and 30 nucleotides are included.

[0091] In some embodiments, the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides in length.

[0092] Nucleic acid molecules are generally used to modulate the expression of a target nucleic acid in a mammal. In some embodiments, nucleic acid molecules (eg, siRNA, shRNA, or antisense oligonucleotides) are generally used to inhibit the expression of a target nucleic acid.

[0093] In one embodiment of the present invention, the nucleic acid molecule is selected from RNAi agents, such as siRNA, shRNA.

[0094] In another embodiment, the nucleic acid molecule is an antisense oligonucleotide, such as a single-stranded antisense oligonucleotide, such as a high affinity modified antisense oligonucleotide that interacts with RNaseH.

[0095] In some embodiments, nucleic acid molecules include phosphorothioate internucleoside bonds. In some embodiments, nucleic acid molecules include phosphorothioate bonds at the 5' end and the 3' end (e.g., independently including 1-3 bonds at each end). In some embodiments, all internucleoside bonds in nucleic acid molecules are composed of phosphorothioate.

[0096] In some embodiments, a nucleic acid molecule can be conjugated to a non-nucleoside moiety (conjugating moiety).

[0097] Oligonucleotides

[0098] As used herein, the term "oligonucleotide" or "therapeutic oligonucleotide", as it is generally understood by the skilled artisan, is defined as a molecule comprising two or more covalently linked nucleosides. Such covalently linked nucleosides may also be referred to as nucleic acid molecules, oligonucleotides or oligomers. Oligonucleotides are typically prepared in the laboratory by solid phase chemical synthesis followed by purification. When referring to the sequence of an oligonucleotide, it is referred to as a sequence or order of the covalently linked nucleotides or nucleosides or their modified nucleobase portions. The oligonucleotides of the present invention are artificial and chemically synthesized and are typically purified or isolated. The oligonucleotides of the present invention may comprise one or more modified nucleosides or nucleotides, such as 2' sugar-modified nucleosides.

[0099] Oligonucleotide of the present invention comprises a continuous nucleotide sequence complementary to target nucleic acid or target sequence, and in some embodiments, in addition to the continuous nucleotide sequence, may further comprise one or more additional nucleotides, such as 1-30, such as 1-20, such as 1-10, such as 1,2,3,4 or 5 additional nucleotides. In some embodiments, the additional nucleotides are complementary to the continuous nucleotide sequence, and can form a stem-loop (hairpin) structure by hybridizing with the continuous nucleotide sequence. In some embodiments, the additional nucleotides are 1 to 5 nucleotides connected by phosphodiester. In some embodiments, all nucleotides of the oligonucleotide form a continuous nucleotide sequence.

[0100] Antisense Oligonucleotides

[0101] The term "antisense oligonucleotide" as used herein is defined as an oligonucleotide that can regulate the expression of a target gene by hybridizing with a target nucleic acid, particularly with a continuous sequence on the target nucleic acid. Antisense oligonucleotides are not substantially double-stranded and are therefore not siRNA or shRNA. Preferably, the antisense oligonucleotides of the present invention are single-stranded. It should be understood that the single-stranded oligonucleotides of the present invention can form a hairpin or an intermolecular duplex structure (a duplex between two molecules of the same oligonucleotide), as long as the degree of self-complementarity within or between oligonucleotides is less than 50% over the total length of the oligonucleotide.

[0102] Advantageously, the single-stranded antisense oligonucleotides of the invention do not contain RNA nucleosides, as this would reduce nuclease resistance.

[0103] Advantageously, the antisense oligonucleotides of the invention comprise one or more modified nucleosides or nucleotides, such as 2' sugar modified nucleosides. Furthermore, advantageously the unmodified nucleosides are DNA nucleosides.

[0104] RNAi or siRNA

[0105] The term "RNA interference (RNAi) molecule" herein refers to any molecule that suppresses RNA expression or translation by reducing the silencing complex (RISC) in the cytoplasm of a cell, wherein the RNAi molecule interacts with the catalytic RISC component argonaute. Small interfering RNA (siRNA) is generally a double-stranded RNA complex comprising a passenger (sense) and a guide (antisense) oligonucleotide (chain), which, when applied to a cell, causes the guide (antisense) chain to be incorporated into the RISC complex (siRISC), causing RISC to suppress translation or degradation of complementary RNA target nucleic acids in the cell. The sense strand is also referred to as the passenger strand, and the antisense strand is also referred to as the guide strand. Small hairpin RNA (shRNA) is a single nucleic acid molecule that forms a stem-loop (hairpin) structure, which can degrade mRNA by RISC. RNAi nucleic acid molecules can be chemically synthesized (typical for siRNA complexes) or synthesized by in vitro transcription, or expressed from a vector.

[0106] shRNA molecules are typically 40 to 70 nucleotides in length, such as 45 to 65 nucleotides in length, such as 50 to 60 nucleotides in length, and interact with an endonuclease called Dicer, which is believed to process the dsRNA into a 19-23 base pair short interfering RNA with a characteristic two base 3' overhang, which is then incorporated into the RNA-induced silencing complex (RISC).

[0107] Typically, the guide (antisense) strand of the siRNA (or the antisense region of the shRNA) is 17-25 nucleotides in length, such as 19-23 nucleotides, and is complementary to the target nucleic acid or target sequence. In the siRNA complex, the guide (antisense) strand and the passenger (sense) strand form a double-stranded duplex that may include, for example, a 1-3 nucleotide 3′ terminal overhang (similar to the product produced by the Dicer), or may be blunt-ended (without an overhang at one or both ends of the duplex).

[0108] It will be appreciated that RNAi can be mediated by longer dsRNA substrates that are processed into siRNAs within the cell (a process believed to involve the dsRNA endonuclease DICER). Effectively extended forms of Dicer substrates have been described in US 8,349,809 and US 8,513,207, which are hereby incorporated by reference.

[0109] RNAi oligonucleotides can be chemically modified using modified internucleotide linkages and high affinity nucleosides, such as 2' sugar modified nucleosides, such as 2'-4' bicyclic ribose modified nucleosides, including LNA and cET or 2' substituted modifications, such as 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-DNA, arabinonucleotide (ANA), 2'-fluoro-ANA. See, for example, WO2002 / 044321, which discloses 2'O-methyl modified siRNAs; WO2004083430, which discloses the use of LNA nucleosides in siRNA complexes, referred to as siLNA; and WO2007107162, which discloses the use of discontinuous passenger chains in siRNAs, such as siLNA complexes. WO03006477 discloses siRNA and shRNA (also known as stRNA) oligonucleotide mediators of RNAi. Harborth et al., Antisense Nucleic Acid Drug Dev. 2003 Apr; 13(2): 83-105 relates to sequence, chemical and structural variations of small interfering RNA and short hairpin RNA and their effects on mammalian gene silencing.

[0110] In some embodiments, RNAi oligonucleotides include one or more thiophosphate nucleoside interkeys. In RNAi molecules, thiophosphate nucleoside interkeys can reduce the nuclease cleavage in RICS, so advantageously, all nucleoside interkeys are not modified. Phosphorothioate nucleoside interkeys can be advantageously located at the 3' and / or 5' ends of RNAi nucleic acid molecules, particularly at the parts of molecules that are not complementary to the target nucleic acid (e.g., sense strands or passenger strands in siRNA molecules). However, regions complementary to the target nucleic acid in RNAi molecules (e.g., antisense or guide strands in siRNA molecules) can also be modified in the first 2 to 3 nucleoside interkeys at 3' and / or 5' ends.

[0111] Continuous nucleotide sequence

[0112] The term "continuous nucleotide sequence" refers to the region of an oligonucleotide complementary to a target nucleic acid. The term is used interchangeably with the term "continuous core base sequence" and the term "oligonucleotide motif sequence" in this article. In some embodiments, all nucleotides of an oligonucleotide constitute a continuous nucleotide sequence. In some embodiments, an oligonucleotide comprises a continuous nucleotide sequence, such as the flank (also referred to as wing) and a gap region of a gapmer, such as a FG-F' gapmer region, and may optionally comprise further nucleotides, such as a nucleotide joint region that can be used to attach a functional group to a continuous nucleotide sequence. The nucleotide joint region may be complementary to the target nucleic acid or may not be complementary to the target nucleic acid.

[0113] Nucleotides

[0114] Nucleotides are the building blocks of oligonucleotides and polynucleotides, and for purposes of the present invention, include naturally occurring and non-naturally occurring nucleotides. In nature, nucleotides, such as DNA and RNA nucleotides, contain a ribose moiety, a core base moiety, and one or more phosphate groups (which are not present in nucleosides). Nucleosides and nucleotides may also be referred to interchangeably as "units" or "monomers."

[0115] Modified Nucleosides

[0116] The term "modified nucleoside" or "nucleoside modification" used herein refers to a nucleoside modified by introducing one or more modifications of a sugar moiety or (core) base moiety compared to an equivalent DNA or RNA nucleoside. In a preferred embodiment, the nucleoside modified comprises a modified sugar moiety. The term modified nucleoside can also be used interchangeably with the term "nucleoside analog" or modified "unit" or modified "monomer" in this article. Nucleosides with unmodified DNA or RNA sugar moieties are referred to as DNA or RNA nucleosides in this article. Nucleosides with modifications in the base region of a DNA or RNA nucleoside are still usually referred to as DNA or RNA if Watson Crick base pairing is allowed.

[0117] Modified internucleoside bonds

[0118] As the technician generally understands, the term "modified internucleoside bond" is defined as a bond that covalently couples two nucleosides together except for a phosphodiester (PO) bond. Therefore, the oligonucleotide of the present invention may include a modified internucleoside bond. In some embodiments, compared with a phosphodiester bond, the modified internucleoside bond increases the nuclease resistance of the oligonucleotide, which is particularly advantageous for therapeutic oligonucleotides. For naturally occurring oligonucleotides, the internucleoside bond includes a phosphate group that produces a phosphodiester bond between adjacent nucleosides. The modified internucleoside bond is particularly useful for stabilizing the oligonucleotide used in vivo, and can be used to protect the DNA or RNA nucleoside region (e.g., in the gap region of a gapmer oligonucleotide, and in the modified nucleoside region, such as F and F' region) in the oligonucleotide of the present invention from nuclease cutting.

[0119] In one embodiment, an oligonucleotide, such as a therapeutic antisense oligonucleotide, shRNA or siRNA, comprises one or more internucleoside bonds modified from a natural phosphodiester, such as one or more modified internucleoside bonds that are more resistant to nuclease attack. Nuclease resistance can be determined by incubating the oligonucleotide in serum or by using a nuclease resistance assay (e.g., snake venom phosphodiesterase (SVPD)), both of which are well known in the art. Internucleoside bonds that can enhance the nuclease resistance of an oligonucleotide are referred to as nucleoside bonds of nuclease resistance. In some embodiments, at least 50% of the internucleoside bonds in an oligonucleotide or its continuous nucleotide sequence are modified, such as at least 60%, such as at least 70%, such as at least 80%, or such as at least 90% of the internucleoside bonds in an oligonucleotide or its continuous nucleotide sequence are nucleoside bonds of nuclease resistance. In some embodiments, all internucleoside bonds in an oligonucleotide or its continuous nucleotide sequence are nucleoside bonds of nuclease resistance. It should be recognized that in some embodiments, the nucleoside connecting the oligonucleotide of the present invention to a non-nucleotide functional group (e.g., a conjugate) can be a phosphodiester.

[0120] A preferred modified internucleoside linkage is phosphorothioate.

[0121] Phosphorothioate internucleoside bonds are particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture. In some embodiments, at least 50% of the internucleoside bonds in an oligonucleotide or its continuous nucleotide sequence are phosphorothioates, and at least 60%, such as at least 70%, such as at least 80% or such as at least 90% of the internucleoside bonds in an oligonucleotide or its continuous nucleotide sequence are phosphorothioates. In some embodiments, all internucleoside bonds of an oligonucleotide or its continuous nucleotide sequence are phosphorothioates. The use of fully phosphorothioate-modified oligonucleotides or continuous nucleotide sequences is generally used for antisense oligonucleotides, although in siRNA, partial phosphorothioate modifications may be preferred because it has been reported that fully phosphorothioate modifications limit RNAi activity, particularly when used for guide (antisense) strands. Phosphorothioate modifications can be incorporated into the 5' and 3' ends of the antisense strand of siRNA without excessively limiting RNAi activity.

[0122] Nuclease-resistant bonds, such as phosphorothioate bonds, are particularly useful in regions of the oligonucleotide that are capable of recruiting nucleases when forming a duplex with a target nucleic acid, such as region G of a gapmer. However, phosphorothioate bonds can also be used in non-nuclease recruiting regions and / or affinity enhancing regions, such as regions F and F' of a gapmer. In some embodiments, a gapmer oligonucleotide may comprise one or more phosphodiester bonds in region F or F' or both regions F and F', wherein the internucleoside bonds in region G may be entirely phosphorothioate. Advantageously, all internucleoside bonds in the contiguous nucleotide sequence of the antisense oligonucleotide are phosphorothioate bonds.

[0123] It is recognized that, as disclosed in EP 2 742 135, antisense oligonucleotides may comprise other internucleoside linkages (besides phosphodiester and phosphorothioate), such as alkylphosphonate / methylphosphonate internucleoside linkages, which according to EP 2 742 135 may for example be tolerated in regions of otherwise DNA phosphorothioate gaps.

[0124] Nucleobase

[0125] The term core base includes purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine and cytosine) moieties present in nucleosides and nucleotides that form hydrogen bonds in nucleic acid hybridization. In the context of the present invention, the term core base also encompasses modified core bases that may be different from naturally occurring core bases, but are functional during nucleic acid hybridization. In this article, "core base" refers to naturally occurring core bases (e.g., adenine, guanine, cytosine, thymine, uracil, xanthine and hypoxanthine) and non-naturally occurring variants. Such variants are, for example, described in Hirao et al. (2012) Accounts of Chemical Research vol 45page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl.37 1.4.1.

[0126] In some embodiments, the nucleobase moiety is modified by changing a purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, such as a nucleobase selected from the group consisting of isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiozolo-cytosine, 5-propynylcytosine, 5-propynyluracil, 5-bromouracil, 5-thiazolo-uracil, 2-thio-uracil, 2′thiothymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.

[0127] The nucleobase moiety can be represented by the letter code for each corresponding nucleobase, for example, A, T, G, C or U, wherein each letter can optionally include a functionally equivalent modified nucleobase. For example, in an exemplary oligonucleotide, the nucleobase moiety is selected from A, T, G, C and 5-methylcytosine. Optionally, for LNA gapmers, 5-methylcytosine LNA nucleosides can be used.

[0128] Modified oligonucleotides

[0129] The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar modified nucleosides and / or modified internucleoside linkages. The term "chimeric" oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.

[0130] Complementarity

[0131] The term "complementarity" describes the ability of the Watson-Crick base pairing of nucleosides / nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U). It will be appreciated that oligonucleotides may comprise nucleosides with modified nucleobases, for example, 5-methylcytosine is often used instead of cytosine, and therefore, the term complementarity encompasses Watson-Crick base pairing between unmodified and modified nucleobases (see, for example, Hirao et al. (2012) Accounts of Chemical Research vol 45page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 371.4.1).

[0132] As used herein, the term "complementary %" refers to the percentage of the number of nucleotides of a continuous nucleotide sequence in an oligonucleotide (e.g., an oligonucleotide) that is complementary to a continuous nucleotide sequence at a given position of a separate oligonucleotide (e.g., a target nucleic acid) (i.e., forms a Watson Crick base pairing formation). The percentage is calculated by counting the number of aligned bases that form a pairing between the two sequences (when the target sequence 5'-3' and the oligonucleotide sequence 3'-5' are aligned), divided by the total number of nucleotides in the oligonucleotide, and multiplied by 100. In this comparison, the nucleobase / nucleotide that is not aligned (forming a base pair) is referred to as a mismatch. Preferably, insertions and deletions are not allowed when calculating the % complementarity of a continuous nucleotide sequence.

[0133] The term "fully complementary" refers to 100% complementarity.

[0134] The following is an example of an oligonucleotide motif (SEQ ID NO: 86) that is completely complementary to a target nucleic acid (SEQ ID NO: 325).

[0135] 5′gaataatatggaaaaacgaaaa 3′(SEQ ID NO:325)

[0136] 3'tattatacctttttgct 5' (SEQ ID NO:86)

[0137] Identity

[0138] As used herein, the term "identity" refers to the ratio (expressed as a percentage) of nucleotides in a continuous nucleotide sequence in an oligonucleotide (e.g., an oligonucleotide) that is identical to a reference sequence (e.g., a sequence motif). Therefore, the identity percentage is calculated by counting the number of aligned bases that are identical (matched) between two sequences (in the continuous nucleotide sequence of the compounds of the present invention and in the reference sequence), dividing the number by the total number of nucleotides in the oligonucleotide and multiplying by 100. Therefore, identity percentage = (number of matches x100) / length of alignment region (e.g., a continuous nucleotide sequence). Insertions and deletions are not allowed in calculating the identity percentage of a continuous nucleotide sequence. It should be understood that when determining identity, chemical modifications of nucleobases can be ignored as long as the functional ability of nucleobases to form Watson Crick base pairing is retained (e.g., for the purpose of calculating % identity, 5-methylcytosine is considered to be identical to cytosine).

[0139] Hybridization

[0140] As used herein, the term "hybridization" is understood to mean the formation of hydrogen bonds between base pairs on opposing strands between two nucleic acid strands (e.g., an oligonucleotide and a target nucleic acid), thereby forming a duplex. The affinity of the binding between the two nucleic acid strands is the strength of the hybridization. It is usually measured in terms of the melting temperature (T m ) is used to describe the melting temperature (T m ) is defined as the temperature at which half of the oligonucleotides form duplexes with the target nucleic acid. Under physiological conditions, T m It is not strictly proportional to affinity (Mergny and Lacroix, 2003, Oligonucleotides 13: 515-537). The standard state Gibbs free energy ΔG° more accurately represents the binding affinity and is given by ΔG° = -RTln(K d ) and the dissociation constant (K d), where R is the gas constant and T is the absolute temperature. Therefore, the very low ΔG° of the reaction between the oligonucleotide and the target nucleic acid reflects the strong hybridization between the oligonucleotide and the target nucleic acid. ΔG° is the energy associated with the reaction, where the aqueous concentration is 1M, the pH is 7, and the temperature is 37°C. The hybridization of the oligonucleotide with the target nucleic acid is a spontaneous reaction, and for a spontaneous reaction, ΔG° is less than zero. ΔG° can be measured experimentally, for example, by using an isothermal titration calorimetry (ITC) method as described in Hansen et al., 965, Chem. Comm. 36–38 and Holdgate et al., 2005, Drug Discov Today. Technicians will know that commercial equipment can be used for ΔG° measurement. ΔG° can also be estimated numerically by using appropriately derived thermodynamic parameters as described in Sugimoto et al., 1995, Biochemistry 34: 11211–11216 and McTigue et al., 2004, Biochemistry 43: 5388–5405 and using the nearest neighbor model as described in SantaLucia, 1998, Proc Natl Acad Sci USA. 95: 1460–1465. In order to have the possibility of modulating its intended nucleic acid target by hybridization, the oligonucleotides of the present invention hybridize to the target nucleic acid with an estimated ΔG° value of less than -10 kcal for oligonucleotides of 10-30 nucleotides in length. In some embodiments, the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. For oligonucleotides of 8-30 nucleotides in length, the oligonucleotide can hybridize to the target nucleic acid with an estimated ΔG° value of less than -10 kcal, such as less than -15 kcal, such as less than -20 kcal, and such as less than -25 kcal. In some embodiments, the oligonucleotide hybridizes to the target nucleic acid with an estimated ΔG° value of -10 to -60 kcal, such as -12 to -40, such as -15 to -30 kcal or -16 to -27 kcal, such as -18 to -25 kcal.

[0141] Target nucleic acid

[0142] According to the present invention, target nucleic acid is a nucleic acid encoding mammalian TMEM106B, and can be, for example, a gene, RNA, mRNA and pre-mRNA, mature mRNA or cDNA sequence. Target can therefore be referred to as TMEM106B target nucleic acid. Oligonucleotides of the present invention can, for example, target the exon region of mammalian TMEM106B RNA, or can, for example, target the intron region in TMEM106B pre-mRNA (see Table 1).

[0143] Table 1: Human TMEM106B exon and intron regions that can be targeted by the compounds of the present invention:

[0144]

[0145]

[0146] Suitably, the target nucleic acid encodes a TMEM106B protein, in particular a mammalian TMEM106B, such as human TMEM106B (see, e.g., Tables 2 and 3, which provide mRNA and pre-mRNA sequences of human, monkey and mouse TMEM106B).

[0147] In some embodiments, the target nucleic acid is selected from SEQ ID NO: 1, 2, 3, 4, 5 and 6 or naturally occurring variants thereof, including SNP variants. Table 4 shows a table of known nucleotide polymorphisms (SNPs) of SEQ ID NO: 1. If the oligonucleotides of the invention are employed in research or diagnosis, the target nucleic acid may be cDNA or a synthetic nucleic acid derived from DNA or RNA.

[0148] The oligonucleotides of the present invention are generally capable of inhibiting the expression of a TMEM106B target nucleic acid in a cell expressing the TMEM106B target nucleic acid. The continuous sequence of nucleobases of the oligonucleotides of the present invention is generally complementary to the TMEM106B target nucleic acid, as measured across the length of the oligonucleotide, optionally except for one or two mismatches, and optionally excluding nucleotide-based linker regions that can connect the oligonucleotide to an optional functional group such as a conjugate, or other non-complementary terminal nucleotides (e.g., region D' or D"). In some embodiments, the target nucleic acid may be a mature mRNA or pre-mRNA.

[0149] In some embodiments, the target nucleic acid is an RNA encoding a mammalian TMEM106B protein, such as human TMEM106B, such as a human TMEM106B pre-mRNA sequence (e.g., a sequence disclosed in SEQ ID NO: 1) or a human mature mRNA (e.g., a sequence disclosed in SEQ ID NO: 2). For further information on exemplary target nucleic acids, see Tables 2 and 3.

[0150] Table 2: Genome and assembly information of TMEM106B from various species.

[0151]

[0152]

[0153] Fwd = forward strand. Rv = reverse strand. Genomic coordinates provide the pre-mRNA sequence (genomic sequence). NCBI reference provides the mRNA sequence (cDNA sequence).

[0154] *The National Center for Biotechnology Information Reference Sequence Database is a comprehensive, integrated, non-redundant, well-annotated reference sequence database, including genomes, transcripts, and proteins. It is hosted at www.ncbi.nlm.nih.gov / refseq.

[0155] Table 3: Sequence details of TMEM106B from various species.

[0156]

[0157] Target sequence

[0158] As used herein, the term "target sequence" refers to a nucleotide sequence present in a target nucleic acid, which comprises a core base sequence complementary to an oligonucleotide of the present invention. In some embodiments, the target sequence is composed of a region of a core base sequence complementary to a continuous nucleotide sequence of an oligonucleotide of the present invention on the target nucleic acid. This region of the target nucleic acid can be interchangeably referred to as a target nucleotide sequence, a target sequence, or a target region. In some embodiments, the target sequence is longer than the complementary sequence of a single oligonucleotide, and can, for example, represent a preferred region of a target nucleic acid that can be targeted by several oligonucleotides of the present invention.

[0159] In some embodiments, the target sequence is present in an intronic region of a TMEM106B nucleic acid (eg, SEQ ID NO: 1).

[0160] In some embodiments, the target sequence is present in exon 9, such as in the 3'UTR of the TMEM106B nucleic acid.

[0161] The inventors have identified that the 3'UTR of human and mouse TMEM106B is a favorable target sequence. In some embodiments, the oligonucleotides of the present invention or their contiguous nucleotide sequences have at least 90% complementarity, such as complete complementarity, with the 3'UTR of mammalian TMEM106B mRNA (e.g., the target nucleic acid referred to herein (e.g., SEQ ID NO: 1, 3 or 5)). In one embodiment, the 3'UTR is located at positions 20755-32146 of SEQ ID NO: 1. As shown in the Examples, the inventors further identified favorable target sequences within the 3'UTR of human TMEM106B transcripts. In some embodiments, the target sequence is from position 20755 to position 26403 of SEQ ID NO: 1. In some embodiments, the target sequence is from position 21084 to position 21213 of SEQ ID NO: 1. In some embodiments, the target sequence is from position 23086 to position 24077 of SEQ ID NO: 1.

[0162] In some embodiments, the target sequence is a sequence selected from the group consisting of human TMEM106B mRNA exons, such as TMEM106B human mRNA exons selected from the group consisting of e1, e2, e3, e4, e5, e6, e7, e8 and e9 (see Table 1 above). In some embodiments, the target sequence is exon e2.

[0163] In some embodiments, the target sequence is a sequence selected from the group consisting of human TMEM106B mRNA introns, such as a TMEM106B human mRNA intron selected from the group consisting of i1, i2, i3, i4, i5, i6, i7 and i8 (see Table 1 above). In some embodiments, the target sequence is intron i8 or the 3'UTR region.

[0164] In some embodiments, the target sequence is selected from a TMEM106B human mRNA intron selected from the group consisting of i1, i2, i3, i4, i5, i6, i7 and i8 and a TMEM106B human mRNA 3'UTR.

[0165] In some embodiments, the target sequence is the sequence of TMEM106B human mRNA intron i8 or 3'UTR (see Table 1 above).

[0166] In some embodiments, the target sequence is or comprises the nucleotide sequence from position 20227 to position 20243 of SEQ ID NO:1.

[0167] In some embodiments, the target sequence is or comprises the nucleotide sequence from position 20227 to position 26403 of SEQ ID NO:1.

[0168] In some embodiments, the target sequence is or comprises the nucleotide sequence from position 20227 to position 21213 of SEQ ID NO:1.

[0169] In some embodiments, the target sequence is or comprises the nucleotide sequence from position 20227 to position 24077 of SEQ ID NO:1.

[0170] Oligonucleotides of the invention comprise a contiguous nucleotide sequence that is complementary to or hybridizes to a target nucleic acid, such as a target sequence described herein.

[0171] The target sequence to which the oligonucleotide is complementary or hybridized generally comprises a continuous nucleobase sequence of at least 10 nucleotides. In some embodiments, such as the antisense oligonucleotides of the present invention, the continuous nucleotide sequence is 10 to 50 nucleotides, such as 10 to 30 nucleotides, such as 14 to 20, such as 15 to 18 continuous nucleotides.

[0172] For siRNA oligonucleotides, the target sequence to which the antisense strand oligonucleotide is complementary or hybridized can include a continuous nucleobase sequence of at least 16 or 17 nucleotides. In some embodiments, the continuous nucleotide sequence is 17 to 25 nucleotides, such as 19 to 23 continuous nucleotides.

[0173] Target cells

[0174] As used herein, the term "target cell" refers to a cell expressing a target nucleic acid. In some embodiments, the target cell can be in vivo or in vitro. In some embodiments, the target cell is a mammalian cell, such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell, such as a monkey cell or a human cell.

[0175] In some embodiments, the target cell is a neuronal cell. In some embodiments, the cell expressing TMEM106B may be a neuronal cell.

[0176] In some embodiments, the target cell expresses TMEM106B mRNA, such as TMEM106B pre-mRNA or TMEM106B mature mRNA. For antisense oligonucleotide targeting, the poly A tail of TMEM106B mRNA is generally not considered.

[0177] In some embodiments, human SK-N-BE(2) neuroblastoma cells obtained from ATCC (CRL-2271) or mouse Neuro-2a neuroblastoma cells obtained from ATCC (CCL-131) can be used to determine whether an oligonucleotide is able to down-regulate a target nucleic acid (see Examples).

[0178] Naturally occurring variants

[0179] The term "naturally occurring variant" refers to a variant of a TMEM106B gene or transcript that is derived from the same genetic locus as the target nucleic acid, but may differ, for example, due to codon diversity encoding the same amino acid due to the degeneracy of the genetic code, or due to alternative splicing of pre-mRNA, or the presence of polymorphisms, such as single nucleotide polymorphisms (SNPs) and allelic variants. Based on the presence of sufficient complementary sequences to the oligonucleotide, the oligonucleotides of the present invention can therefore target the target nucleic acid and its naturally occurring variants.

[0180] In some embodiments, the naturally occurring variant has at least 95%, such as at least 98% or at least 99% homology to a mammalian TMEM106B target nucleic acid, such as a target nucleic acid selected from SEQ ID NO 1-6. In some embodiments, the naturally occurring variant has at least 99% homology to a human TMEM106B target nucleic acid of SEQ ID NO: 1 or SEQ ID NO 2. In some embodiments, the naturally occurring variant is a polymorphism listed in Table 4.

[0181] Table 4: Examples of known single nucleotide polymorphisms in the human TMEM106B gene (the human pre-mRNA start / reference sequence is SEQ ID NO 1).

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190] Regulation of expression

[0191] As used herein, the term "regulation of expression" is understood to be a general term for the ability of an oligonucleotide to change the amount of TMEM106B when compared to the amount of TMEM106B before the oligonucleotide is administered. Alternatively, the regulation of expression can be determined by reference to a control experiment. It is generally understood that a control is an individual or target cell treated with a saline composition or an individual or target cell treated with a non-targeted oligonucleotide (mimetic).

[0192] One type of regulation is the ability of the oligonucleotide to inhibit, down-regulate, reduce, suppress, remove, stop, block, prevent, alleviate, reduce, avoid or terminate TMEM106B expression, such as by degrading mRNA or blocking transcription. Another type of regulation is the ability of the oligonucleotide to restore, increase or enhance TMEM106B expression, such as by repairing splicing sites or preventing splicing or removing or blocking inhibitory mechanisms (such as microRNA inhibition).

[0193] High affinity modified nucleosides

[0194] High affinity modified nucleosides are modified nucleotides that, when incorporated into an oligonucleotide, enhance the affinity of the oligonucleotide for its complementary target, for example by increasing the melting temperature (T m ). The high affinity modified nucleosides of the present invention preferably increase the melting temperature of each modified nucleoside by +0.5 to +12°C, more preferably +1.5 to +10°C, and most preferably +3 to +8°C. Many high affinity modified nucleosides are known in the art, and include, for example, many 2' substituted nucleosides and locked nucleic acids (LNA) (see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3 (2), 293-213).

[0195] Sugar modification

[0196] The oligomers of the invention may comprise one or more nucleosides having a modified sugar moiety, ie, a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.

[0197] Many nucleosides with modifications to the ribose sugar moiety have been prepared, primarily with the goal of improving certain properties of the oligonucleotide, such as affinity and / or nuclease resistance.

[0198] Such modification includes those modifications in which the ribose ring structure is modified, for example, by replacing with the following structure: hexose ring (HNA), or dicyclo, the ring usually has a diradicle (biradicle) bridge between the C2 and C4 carbon atoms of a ribose ring (LNA), or usually lacks a non-connected ribose ring (such as UNA) of a key between C2 and C3 carbon. Other sugar-modified nucleosides include, for example, dicyclohexose nucleic acids (WO2011 / 017521) or tricyclic nucleic acids (WO2013 / 154798). The nucleosides of modification also include nucleosides in which sugar moieties are replaced by non-sugar moieties, for example, in the case of peptide nucleic acids (PNA) or morpholino nucleic acids.

[0199] Sugar modifications also include modifications by changing the substituents on the ribose ring to groups other than hydrogen or to the 2'-OH group naturally present in DNA and RNA nucleosides. For example, substituents can be introduced at the 2', 3', 4' or 5' positions.

[0200] 2' sugar modified nucleosides

[0201] 2' sugar modified nucleosides are nucleosides that have a substituent other than H or -OH at the 2' position (2' substituted nucleosides), or contain a 2' linked diradical capable of forming a bridge between the 2' carbon and the second carbon in the ribose ring, such as LNA (2'-4' diradical bridged) nucleosides.

[0202] Indeed, much attention has been focused on developing 2' substituted nucleosides, and it has been found that many 2' substituted nucleosides have beneficial properties when incorporated into oligonucleotides. For example, 2' modified sugars can provide enhanced binding affinity and / or increased nuclease resistance to oligonucleotides. Examples of 2'-substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. For further examples, see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3 (2), 293-213, and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2' substituted modified nucleosides.

[0203]

[0204] With respect to the present invention, 2' substitution does not include 2' bridging molecules like LNA.

[0205] Locked Nucleic Acid (LNA)

[0206] "LNA nucleosides" are 2'-modified nucleosides that contain a double radical connecting the C2' and C4' of the ribose sugar ring of the nucleoside (also called a "2'-4' bridge"), which constrains or locks the conformation of the ribose ring. These nucleosides are also called bridged nucleic acids or bicyclic nucleic acids (BNA) in the literature. When LNA is incorporated into an oligonucleotide complementary to an RNA or DNA molecule, the locking of the ribose conformation is associated with an enhanced affinity for hybridization (duplex stabilization). This can be routinely determined by measuring the melting temperature of the oligonucleotide / complementary sequence duplex.

[0207] Non-limiting exemplary LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352, WO 2004 / 046160, WO 00 / 047599, WO 2007 / 134181, WO 2010 / 077578, WO 2010 / 036698, WO 2007 / 090071, WO 2009 / 006478, WO 2011 / 156202, WO 2008 / 154401, WO 2009 / 067647, WO 2008 / 150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol. 75(5) pp.1569-81, and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, and Wan and Seth, J. Medical Chemistry 2016, 59, 9645-9667.

[0208] Further non-limiting exemplary LNA nucleosides are disclosed in Scheme 1.

[0209] Scenario 1:

[0210]

[0211] Particular LNA nucleosides are β-D-oxy-LNA, 6'-methyl-β-D-oxy-LNA, such as (S)-6'-methyl-β-D-oxy-LNA (ScET) and ENA.

[0212] A particularly advantageous LNA is β-D-oxy-LNA.In some embodiments, the oligonucleotides of the invention comprise at least one β-D-oxy-LNA or 6'-methyl-β-D-oxy-LNA nucleoside.

[0213] Nuclease-mediated degradation

[0214] Nuclease-mediated degradation refers to an oligonucleotide that is capable of mediating the degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.

[0215] In some embodiments, the oligonucleotides may function by nuclease-mediated degradation of the target nucleic acid, wherein the oligonucleotides of the invention are capable of recruiting nucleases, particularly endonucleases, preferably endoribonucleases (RNases), such as RNase H. Examples of oligonucleotide designs that function by a nuclease-mediated mechanism are oligonucleotides that typically comprise a region of at least 5 or 6 contiguous DNA nucleosides and are flanked on one or both sides by affinity-enhancing nucleosides, such as gapmers, headmers and tailmers.

[0216] RNase H activity and recruitment

[0217] The RNase H activity of an antisense oligonucleotide refers to the ability to recruit RNase H when it forms a duplex with a complementary RNA molecule. WO01 / 23613 provides an in vitro method for determining RNase H activity, which can be used to determine the ability to recruit RNase H. Under the following conditions, it is considered that the oligonucleotide can recruit RNase H: if the oligonucleotide, when provided with a complementary target nucleic acid sequence, has an initial rate (in pmol / l / min) of at least 5%, such as at least 10% or greater than 20% of the following initial rate, wherein the initial rate is when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested but only comprising a DNA monomer having a phosphorothioate bond between all monomers in the oligonucleotide and using the method provided by WO01 / 23613 Examples 91-95 (incorporated herein by reference). In order to be used to determine RHase H activity, recombinant human RNase H1 can be obtained from Lubio Science GmbH, Lucerne, Switzerland.

[0218] Gapmer

[0219] The antisense oligonucleotide of the present invention or its continuous nucleotide sequence can be a gapmer. Antisense gapmers are generally used to inhibit target nucleic acids by RNase H-mediated degradation. Gapmer oligonucleotides contain at least three different structural regions, namely the 5' flank, the gap and the 3' flank, FG-F' in the '5->3' direction. The "gap" region (G) contains a stretch of continuous DNA nucleotides that enable the oligonucleotide to recruit RNase H. The flanks of the gap region are the 5' flank region (F) and the 3' flank region (F'), wherein the 5' flank region (F) contains one or more sugar-modified nucleosides, advantageously high-affinity sugar-modified nucleosides, wherein the 3' flank region (F') contains one or more sugar-modified nucleosides, advantageously high-affinity sugar-modified nucleosides. One or more sugar-modified nucleosides in the F and F' regions enhance the affinity of the oligonucleotide to the target nucleic acid (i.e., are affinity-enhanced sugar-modified nucleosides). In some embodiments, one or more sugar-modified nucleosides in regions F and F' are 2' sugar-modified nucleosides, such as high affinity 2' sugar modifications, such as independently selected from LNA and 2'-MOE.

[0220] In the gapmer design, the 5'-most and 3'-most nucleosides of the gap region are DNA nucleosides, located near the sugar-modified nucleosides of the 5' (F) or 3' (F') regions, respectively. The flanks can be further defined as having at least one sugar-modified nucleoside at the ends farthest from the gap region, i.e., at the 5' end of the 5' flank and the 3' end of the 3' flank. The region FG-F' forms a continuous nucleotide sequence. The antisense oligonucleotide of the present invention or its continuous nucleotide sequence may comprise a gapmer region of formula FG-F'.

[0221] The total length of the gapmer design FG-F' can be, for example, 12 to 32 nucleosides, such as 13 to 24 nucleosides, such as 14 to 22 nucleosides, such as 14 to 17 nucleosides, such as 16 to 18 nucleosides.

[0222] For example, the gapmer oligonucleotide of the present invention can be represented by the following formula:

[0223] F 1-8 -G 5-16 -F' 1-8 ,For example

[0224] F 1-8 -G 7-16 -F' 2-8

[0225] Provided that the total length of the gapmer region FG-F' is at least 12, such as at least 14 nucleotides long.

[0226] Regions F, G and F' are further defined below and may be incorporated into the general formula FG-F'.

[0227] Gapmer - Region G

[0228] The region G (gap region) of the gapmer is a region of nucleosides that enables the oligonucleotide to recruit RNAaseH, such as human RNase H1, typically DNA nucleosides. RNaseH is a cellular enzyme that recognizes duplexes between DNA and RNA and cleaves RNA molecules. Suitably, the gapmer may have a gap region (G) of at least 5 or 6 consecutive DNA nucleosides, such as 5-16 consecutive DNA nucleosides, such as 6-15 consecutive DNA nucleosides, such as 7-14 consecutive DNA nucleosides, such as 8-12 consecutive DNA nucleotides, such as 8-12 consecutive DNA nucleotides. In some embodiments, the gap region G may consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 consecutive DNA nucleosides. In some cases, one or more cytosine (C) DNA in the gap region may be methylated (for example, when DNAc is followed by DNAg), and these residues are annotated as 5-methylcytosine ( me C). In some embodiments, the gap region G can consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 consecutive phosphorothioate linked DNA nucleosides. In some embodiments, all internucleoside bonds in the gap are phosphorothioate bonds.

[0229] Although traditional gapmers have a DNA gap region, there are many examples of modified nucleosides that, when used within the gap region, can recruit RNase H. Modified nucleosides that have been reported to be able to recruit RNase H when contained within the gap region include, for example, α-L-LNA, C4' alkylated DNA (as described in PCT / EP2009 / 050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both of which are incorporated herein by reference), arabinose-derived nucleosides such as ANA and 2'F-ANA (Mangos et al. 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039, incorporated herein by reference). UNA is an unlocked nucleic acid, typically a ribose in which the bond between C2 and C3 has been removed to form an unlocked "sugar" residue. The modified nucleosides used for such gapmers can be nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region, i.e., modifications that allow RNaseH recruitment. In some embodiments, the DNA gap region (G) described herein can optionally include 1 to 3 sugar-modified nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region.

[0230] Region G - "Gap Fracture"

[0231] Alternatively, there are many reports on inserting modified nucleosides, which confer 3' endo conformation into the gap region of gapmer while retaining some RNaseH activity. Such gapmers with a gap region containing one or more 3' endo modified nucleosides are referred to as "gap-breakers" or "gap-destroying" gapmers, see, for example, WO2013 / 022984. Gap-breaking oligonucleotides retain enough DNA nucleoside regions in the gap region to allow RNaseH to be recruited. The ability of gap-breaking oligonucleotides to recruit RNaseH is usually sequence-specific or even compound-specific-see Rukov et al., 2015 Nucl. Acids Res. Vol. 43 pp. 8476-8487, which discloses "gap-breaking" oligonucleotides for recruiting RNaseH, which provide more specific cutting of target RNA in some cases. The modified nucleoside used in the gap region of the gap-breaking oligonucleotide can be, for example, a modified nucleoside that confers 3′ endo confirmation, such as a 2′-O-methyl (OMe) or 2′-O-MOE (MOE) nucleoside or a β-D LNA nucleoside (the bridge between C2′ and C4′ of the ribose sugar ring of the nucleoside is in the β conformation), such as a β-D-oxy LNA or ScET nucleoside.

[0232] As with the above-described gapmers containing region G, the gap region of the gap-fragmented or gap-destroyed gapmers has a DNA nucleoside at the 5' end of the gap (adjacent to the 3' nucleoside of region F) and a DNA nucleoside at the 3' end of the gap (adjacent to the 5' nucleoside of region F'). Gapmers containing a destroyed gap typically retain a region of at least 3 or 4 consecutive DNA nucleosides at the 5' or 3' end of the gap region.

[0233] Exemplary designs of nick break oligonucleotides include

[0234] F 1-8 -[D 3-4 -E1-D 3-4 ] - F' 1-8

[0235] F 1-8 -[D 1-4 -E1-D 3-4 ]-F' 1-8

[0236] F 1-8 -[D 3-4 -E1-D 1-4 ]-F' 1-8

[0237] The region G is in brackets [Dn -E r -D m ] wherein D is a continuous sequence of DNA nucleosides, E is a modified nucleoside (a gap break or a gap destroying nucleoside), and F and F' are flanking regions as defined herein, and provided that the total length of the gapmer region FGF' is at least 12, e.g., at least 14 nucleotides long.

[0238] In some embodiments, the region G of the gapmer of the gap comprises at least 6 DNA nucleosides, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 DNA nucleosides. As described above, the DNA nucleosides can be continuous or can be optionally interspersed with one or more modified nucleosides, provided that the gap region G is capable of mediating RNaseH recruitment.

[0239] Gapmer - flanking regions, F and F'

[0240] Region F is immediately adjacent to the 5' DNA nucleoside of region G. The 3'-most nucleoside of region F is a sugar-modified nucleoside, such as a high affinity sugar-modified nucleoside, such as a 2'-substituted nucleoside, such as a MOE nucleoside or a LNA nucleoside.

[0241] Region F' is immediately adjacent to the 3' DNA nucleosides of region G. The 5'-most nucleoside of region F' is a sugar-modified nucleoside, such as a high affinity sugar-modified nucleoside, such as a 2'-substituted nucleoside, such as a MOE nucleoside or a LNA nucleoside.

[0242] The length of region F is 1-8 consecutive nucleotides, such as 2-6, such as 3-4 consecutive nucleotides. Advantageously, the most 5' nucleoside of region F is a sugar-modified nucleoside. In some embodiments, the two most 5' nucleosides of region F are sugar-modified nucleosides. In some embodiments, the most 5' nucleosides of region F are LNA nucleosides. In some embodiments, the two most 5' nucleosides of region F are LNA nucleosides. In some embodiments, the two most 5' nucleosides of region F are 2' substituted nucleosides, such as two 3' MOE nucleosides. In some embodiments, the most 5' nucleosides of region F are 2' substituted nucleosides, such as MOE nucleosides.

[0243] The length of region F' is 2-8 consecutive nucleotides, such as 3-6, such as 4-5 consecutive nucleotides. Advantageously, in embodiments, the 3'-most nucleoside of region F' is a sugar-modified nucleoside. In some embodiments, the two 3'-most nucleosides of region F' are sugar-modified nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are LNA nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are LNA nucleosides. In some embodiments, the two 3'-most nucleosides of region F' are 2'-substituted nucleosides, such as two 3'MOE nucleosides. In some embodiments, the 3'-most nucleosides of region F' are 2'-substituted nucleosides, such as MOE nucleosides.

[0244] It should be noted that when region F or F' has a length of 1, it is advantageously an LNA nucleoside.

[0245] In some embodiments, regions F and F' independently consist of or include a continuous sequence of sugar-modified nucleosides. In some embodiments, the sugar-modified nucleosides of region F may be independently selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units.

[0246] In some embodiments, regions F and F' independently comprise LNA and 2' substituted modified nucleosides (mixed wing design).

[0247] In some embodiments, regions F and F' consist of only one type of sugar-modified nucleosides, such as only MOE or only β-D-oxy LNA or only ScET.Such a design is also referred to as a uniform flank or uniform gapmer design.

[0248] In some embodiments, all nucleosides of region F or F', or F and F' are LNA nucleosides, for example independently selected from β-D-oxy LNA, ENA or ScET nucleosides. In some embodiments, region F consists of 1-5, for example 2-4, for example 3-4, for example 1, 2, 3, 4 or 5 consecutive LNA nucleosides. In some embodiments, all nucleosides of regions F and F' are β-D-oxy LNA nucleosides.

[0249] In some embodiments, all nucleosides of region F or F', or F and F' are 2'substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, region F consists of 1, 2, 3, 4, 5, 6, 7 or 8 consecutive OMe or MOE nucleosides. In some embodiments, only one of the flanking regions may consist of 2'substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, it is a 5'(F) flanking region consisting of 2'substituted nucleosides, such as OMe or MOE nucleosides, and the 3'(F') flanking region comprises at least one LNA nucleoside, such as β-D-oxy LNA nucleosides or cET nucleosides. In some embodiments, it is a 3'(F') flanking region consisting of 2'substituted nucleosides, such as OMe or MOE nucleosides, and the 5'(F) flanking region comprises at least one LNA nucleoside, such as β-D-oxy LNA nucleosides or cET nucleosides.

[0250] In some embodiments, all modified nucleosides of regions F and F' are LNA nucleosides, for example independently selected from β-D-oxy LNA, ENA or ScET nucleosides, wherein region F or F', or F and F' may optionally contain DNA nucleosides (alternating flanks, see these definitions for more information). In some embodiments, all modified nucleosides of regions F and F' are β-D-oxy LNA nucleosides, wherein region F or F', or F and F' may optionally contain DNA nucleosides (alternating flanks, see these definitions for more information).

[0251] In some embodiments, the 5'-most and 3'-most nucleosides of regions F and F' are LNA nucleosides, such as β-D-oxy LNA nucleosides or ScET nucleosides.

[0252] In some embodiments, the internucleoside bond between region F and region G is a phosphorothioate internucleoside bond. In some embodiments, the internucleoside bond between region F' and region G is a phosphorothioate internucleoside bond. In some embodiments, the internucleoside bond between nucleosides of region F or F', F and F' is a phosphorothioate internucleoside bond.

[0253] LNA Gapmer

[0254] An LNA gapmer is a gapmer wherein one or both of regions F and F' comprise or consist of LNA nucleosides. A β-D-oxy gapmer is a gapmer wherein one or both of regions F and F' comprise or consist of β-D-oxy LNA nucleosides.

[0255] In some embodiments, the general formula of the LNAgapmer is: [LNA] 1–5 -[Region G]-[LNA] 1-5, wherein region G is as defined in the definition of gapmer region G.

[0256] MOE Gapmer

[0257] A MOE gapmer is a gapmer in which regions F and F' consist of MOE nucleosides. In some embodiments, a MOE gapmer is designed as [MOE] 1-8 -[Region G]-[MOE] 1-8 , for example [MOE] 2-7 -[Area G] 5-16 -[MOE] 2-7 , for example [MOE] 3-6 -[Region G]-[MOE] 3-6 , wherein region G is as defined in the gapmer definition. MOE gapmers (MOE-DNA-MOE) with a 5-10-5 design have been widely used in the art.

[0258] Hybrid wing gapmer

[0259] The hybrid wing gapmer is an LNA gapmer in which one or both of regions F and F' comprise 2'-substituted nucleosides, for example 2'-substituted nucleosides independently selected from the group consisting of: 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units, for example MOE nucleosides. In some embodiments in which at least one of regions F and F' or both regions F and F' comprise at least one LNA nucleoside, the remaining nucleosides of regions F and F' are independently selected from MOE and LNA. In some embodiments of hybrid wings, one or both regions F and F' may further comprise one or more DNA nucleosides.

[0260] Mixed-wing gapmer designs are disclosed in WO2008 / 049085 and WO2012 / 109395, both of which are incorporated herein by reference.

[0261] Alternate-flank gapmer

[0262] Oligonucleotides with alternating flanks are LNA gapmer oligonucleotides, wherein at least one flank (F or F') comprises DNA in addition to LNA nucleosides. In some embodiments, at least one of regions F or F', or both regions F and F', comprises both LNA nucleosides and DNA nucleosides. In such embodiments, the flank regions F or F', or both F and F', comprise at least three nucleosides, wherein the 5'-most and 3'-most nucleosides of the F and / or F' regions are LNA nucleosides.

[0263] In some embodiments, at least one of regions F or F', or both regions F and F', comprises both LNA nucleosides and DNA nucleosides. In such embodiments, flanking regions F or F', or both F and F', comprise at least three nucleosides, wherein the 5'-most and 3'-most nucleosides of the F or F' region are LNA nucleosides, and there is at least one DNA nucleoside located between the 5'-most and 3'-most LNA nucleosides of region F or F' (or both regions F and F').

[0264] Region D' or D" in the oligonucleotide

[0265] In some embodiments, an oligonucleotide of the invention may comprise or consist of a contiguous nucleotide sequence of an oligonucleotide complementary to a target nucleic acid, such as gapmer FGF', and further 5' and / or 3' nucleosides. The further 5' and / or 3' nucleosides may or may not be fully complementary to the target nucleic acid. Such further 5' and / or 3' nucleosides may be referred to herein as regions D' and D".

[0266] The addition of region D′ or D″ can be used for the purpose of linking a contiguous nucleotide sequence, such as a gapmer, to a conjugate moiety or another functional group. When used to link a contiguous nucleotide sequence to a conjugate moiety, it can be used as a biocleavable linker. Alternatively, it can be used to provide exonuclease protection or ease of synthesis or manufacturing.

[0267] Regions D' and D" can be attached to the 5' end of region F or the 3' end of region F', respectively, to generate designs of the following general formula: D'-FG-F', FG-F'-D" or D'-FG-F'-D'. In this case, FGF' is the gapmer portion of the oligonucleotide and region D' or D" constitutes a separate portion of the oligonucleotide.

[0268] Region D′ or D″ may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. The nucleotides adjacent to the F or F′ region are not sugar-modified nucleotides, such as DNA or RNA or base-modified versions of these. The D′ or D″ region may be used as a nuclease-sensitive, bio-cleavable linker (see definition of linker). In some embodiments, the additional 5′ and / or 3′ terminal nucleotides are linked to a phosphodiester bond and are DNA or RNA. Nucleotide-based bio-cleavable linkers suitable for use as region D′ or D″ are disclosed in WO2014 / 076195, which include, for example, phosphodiester-linked DNA dinucleotides. The use of bio-cleavable linkers in poly-oligonucleotide constructs is disclosed in WO2015 / 113922, where they are used to link multiple antisense constructs (e.g., gapmer regions) within a single oligonucleotide.

[0269] In one embodiment, the oligonucleotide of the present invention comprises a region D' and / or D" in addition to the continuous nucleotide sequence constituting the gapmer.

[0270] In some embodiments, the oligonucleotides of the invention can be represented by the following formula:

[0271] FG-F'; especially F 1-8 -G 5-16 -F' 2-8

[0272] D'-FG-F', especially D' 1-3 -F 1-8 -G 5-16 -F' 2-8

[0273] FG-F'-D", especially F 1-8 -G 5-16 -F' 2-8 -D" 1-3

[0274] D'-FG-F'-D", especially D' 1-3 -F 1-8 -G 5-16 -F' 2-8 -D" 1-3

[0275] In some embodiments, the internucleoside bond between region D′ and region F is a phosphodiester bond. In some embodiments, the internucleoside bond between region F′ and region D″ is a phosphodiester bond.

[0276] Conjugate

[0277] The term conjugate as used herein refers to an oligonucleotide covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).

[0278] The conjugation of the oligonucleotide of the present invention to one or more non-nucleotide parts can improve the pharmacology of the oligonucleotide, for example, by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide. In some embodiments, the conjugate part modifies or enhances the pharmacokinetic properties of the oligonucleotide by improving the cellular distribution, bioavailability, metabolism, excretion, permeability and / or cellular uptake of the oligonucleotide. In particular, the conjugate can target the oligonucleotide to a specific organ, tissue or cell type, thereby enhancing the effectiveness of the oligonucleotide in the organ, tissue or cell type. At the same time, the conjugate can be used to reduce the activity of the oligonucleotide in non-target cell types, tissues or organs, such as off-target activity or activity in non-target cell types, tissues or organs.

[0279] In one embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of: a carbohydrate, a cell surface receptor ligand, a drug, a hormone, a lipophilic substance, a polymer, a protein, a peptide, a toxin (e.g., a bacterial toxin), a vitamin, a viral protein (e.g., a capsid), or a combination thereof.

[0280] In some embodiments, the conjugate is an antibody or antibody fragment with specific affinity for transferrin receptor, for example as disclosed in WO 2012 / 143379, which is incorporated herein by reference. In some embodiments, the non-nucleotide moiety is an antibody or antibody fragment, for example an antibody or antibody fragment that facilitates delivery across the blood-brain barrier, in particular an antibody or antibody fragment that targets transferrin receptor.

[0281] Connectors

[0282] A bond or linker is a connection between two atoms that connects one chemical group or moiety of interest to another chemical group or moiety of interest through one or more covalent bonds. The conjugate moiety can be attached to the oligonucleotide directly or through a linker (e.g., a linker or tether). The linker is used to covalently link a third region, such as a conjugate moiety (region C), to a first region, such as an oligonucleotide or a continuous nucleotide sequence or a gapmer region FGF′ (region A).

[0283] In some embodiments of the present invention, the conjugate or oligonucleotide conjugate of the present invention may optionally include a linker region (second region or region B and / or region Y) located between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate portion (region C or third region).

[0284] Region B refers to a biocleavable linker that comprises or consists of a physiologically labile bond that is cleavable under conditions normally encountered in mammals or similar thereto. Conditions under which the physiologically labile linker undergoes chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidizing or reducing conditions or reagents, and salt concentrations encountered or similar thereto in mammalian cells. Conditions within mammalian cells also include the presence of enzymatic activity normally present in mammalian cells, such as enzymatic activity from proteases or hydrolases or nucleases. In one embodiment, the biocleavable linker is sensitive to cleavage by S1 nuclease. DNA phosphodiesters comprising biocleavable linkers are described in more detail in WO 2014 / 076195 (incorporated herein by reference) - see also region D′ or D″ herein.

[0285] Region Y refers to a linker that is not necessarily biocleavable but is primarily used to covalently link the conjugate portion (region C or the third region) to the oligonucleotide (region A or the first region). The region Y linker may comprise a chain structure or repeating units such as ethylene glycol, an oligomer of an amino acid unit or an aminoalkyl group. The oligonucleotide conjugates of the present invention can be constructed from the following region elements AC, ABC, ABYC, AYBC or AYC. In some embodiments, the linker (region Y) is an aminoalkyl group, such as a C2-C36 aminoalkyl group, including, for example, a C6 to C12 aminoalkyl group. In a preferred embodiment, the linker (region Y) is a C6 aminoalkyl group.

[0286] treat

[0287] The term "treatment" as used herein refers to the treatment of an existing disease (e.g., a disease or condition referred to herein), or the prevention of a disease, i.e., prevention. Therefore, it will be appreciated that in some embodiments, the treatment referred to herein may be preventive. In some embodiments, treatment is performed on a patient diagnosed with a neurological disorder, such as a neurological disorder selected from the group consisting of: neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinated leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, cortical basal syndrome, progressive supranuclear palsy, and neuronal ceroid lipofuscinosis (NCL).

[0288] In some embodiments, compounds of the invention are used to treat frontotemporal lobar degeneration (FTLD).

[0289] The desired effect of treatment is to reduce the TMEM106B mRNA in the frontal cortex of the subject to be treated to a normal level, which corresponds to the average TMEM106B mRNA level of a non-demented individual. Advantageously, the reduction of TMEM106B mRNA will not be less than 40% of the normal level, such as 30% below the normal level, such as 20% below the normal level, such as within the range of 40% below the normal level and 20% above the normal level, such as 30% below the normal level and 15% above the normal level, such as 20% below the normal level and 20% above the normal level.

[0290] Pharmaceutically acceptable salts

[0291] The term "pharmaceutically acceptable salt" refers to those salts that retain the biological effectiveness and properties of free alkali or free acid, which are not biologically or otherwise undesirable. The salt is formed by inorganic acid and organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, particularly hydrochloric acid, and organic acid such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine. In addition, these salts can be prepared by adding inorganic alkali or organic base to the free acid. Salts derived from inorganic alkali include but are not limited to sodium, potassium, lithium, ammonium, calcium, magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins. Formula (I) compounds can also exist in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of formula (I) compounds are hydrochlorides, hydrobromides, sulfates, phosphates and mesylate.

[0292] Protecting Group

[0293] The term "protecting group" used alone or in combination refers to a group that selectively blocks a reactive site in a multifunctional compound so that a chemical reaction can be selectively carried out at another unprotected reactive site. The protecting group can be removed. Exemplary protecting groups are amino protecting groups, carboxyl protecting groups, or hydroxyl protecting groups. DETAILED DESCRIPTION

[0294] Oligonucleotides of the present invention

[0295] The present invention relates to oligonucleotides capable of regulating TMEM106B expression, such as inhibiting (downregulating) TMEM106B. Regulation is achieved by hybridizing with a target nucleic acid encoding TMEM106B or participating in TMEM106B regulation. The target nucleic acid can be a mammalian TMEM106B sequence, such as a sequence selected from SEQ ID NO: 1-6.

[0296] Advantageously, the oligonucleotide of the invention may be selected from antisense oligonucleotides, siRNA or shRNA targeting TMEM106B.

[0297] In some embodiments, the oligonucleotides of the invention are capable of modulating the expression of a target by inhibiting or down-regulating the expression of the target. Preferably, such modulation produces at least 20% inhibition of expression compared to the normal expression level of the target, more preferably, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% inhibition of expression compared to the normal expression level of the target. In some embodiments, the oligonucleotides of the invention may be capable of inhibiting the expression level of TMEM106B mRNA in vitro by at least 60% or 70%, using human SK-N-BE (2) neuroblastoma cells, which can be obtained from ATCC (CRL-2271). In some embodiments, using human SK-N-BE (2) neuroblastoma cells, the compounds of the invention may be capable of inhibiting the expression level of TMEM106B protein in vitro by at least 50%. Suitably, the Examples provide assays that can be used to measure TMEM106B RNA or protein inhibition. Target regulation is triggered by hybridization between the continuous nucleotide sequence of the oligonucleotide and the target nucleic acid. In some embodiments, the oligonucleotide of the present invention comprises a mismatch between the oligonucleotide and the target nucleic acid. Despite the presence of a mismatch, hybridization with the target nucleic acid may still be sufficient to show the desired TMEM106B expression regulation. The reduction in binding affinity caused by mismatch can be advantageously compensated by an increase in the number of nucleotides in the oligonucleotide and / or an increase in the number of modified nucleosides that can increase affinity with the target, the modified nucleosides being, for example, 2' sugar-modified nucleosides present in the oligonucleotide sequence, including LNA.

[0298] One aspect of the invention relates to an antisense oligonucleotide comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length having at least 90% complementarity to a mammalian TMEM106B nucleic acid (eg, SEQ ID NOs: 1-6, eg, SEQ ID NOs: 1, 2, 3, 4, 5, or 6).

[0299] In some embodiments, the oligonucleotide comprises a contiguous sequence of 10 to 30 nucleotides in length that is at least 90% complementary to a target nucleic acid or a region of a target sequence, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98% or 100% complementary.

[0300] In preferred embodiments, the oligonucleotides of the invention or contiguous nucleotide sequences thereof are completely complementary (100% complementary) to a region of the target nucleic acid, or in some embodiments may contain one or two mismatches between the oligonucleotide and the target nucleic acid.

[0301] In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is at least 90% complementary, e.g., completely (or 100%) complementary, to a target nucleic acid region present in SEQ ID NO: 1 and / or 2. In some embodiments, the oligonucleotide sequence is 100% complementary to the corresponding target nucleic acid region present in SEQ ID NO: 1 and SEQ ID NO: 3 or SEQ ID NO 5 (or SEQ ID NO: 3 and 5). In some embodiments, the oligonucleotide sequence is 100% complementary to the corresponding target nucleic acid region present in SEQ ID NO: 1, 3, and 5.

[0302] In some embodiments, the oligonucleotide sequence is 100% complementary to the corresponding target nucleic acid regions present in SEQ ID NO: 2 and SEQ ID NO: 4 or SEQ ID NO 6 (or SEQ ID NO: 4 and 6). In some embodiments, the oligonucleotide sequence is 100% complementary to the corresponding target nucleic acid regions present in SEQ ID NO: 2, 4 and 6.

[0303] In some embodiments, the oligonucleotide of the invention is at least 90% complementary to exon 9 of SEQ ID NO 1, such as 100% complementary.

[0304] In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length, which has at least 90% complementarity, such as 100% complementarity, to the corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of Reg.A1 to A80 in Table 5.

[0305] Table 5: Selected regions of SEQ ID NO: 1 that can be targeted using the oligonucleotides of the invention

[0306]

[0307] In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length, which has at least 90% complementarity, such as 100% complementarity, to the corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of Reg B1 to B29 in Table 6.

[0308] Table 6: Selected regions of SEQ ID NO: 2 that can be targeted using the oligonucleotides of the invention

[0309]

[0310] In some embodiments, the oligonucleotide of the invention comprises or consists of 8 to 70 nucleotides in length, such as 10 to 60 nucleotides in length, such as 10 to 50 nucleotides in length, such as 12 to 50 nucleotides in length, such as 8 to 40 nucleotides in length, such as 9 to 35, such as 10 to 30, such as 11 to 22, such as 12 to 20, such as 13 to 18 or 14 to 16 nucleotides in length.

[0311] In some embodiments, the antisense-oligonucleotide of the invention or its contiguous nucleotide sequence comprises or consists of a length of 10 to 35 nucleotides, such as a length of 10 to 30, such as 11 to 22, such as 12 to 20, such as 14 to 18 or 14 to 16 consecutive nucleotides. Advantageously, the antisense-oligonucleotide or its contiguous nucleotide sequence comprises or consists of a length of 14, 15, 16, 17 or 18 nucleotides.

[0312] In some embodiments, the antisense oligonucleotide or its continuous nucleotide sequence comprises 22 or less nucleotides, for example 20 or less nucleotides, for example 18 or less nucleotides, for example 14,15,16 or 17 nucleotides, or consists of it.It should be understood that any range given herein includes range endpoints.Therefore, if it is said that the oligonucleotide comprises 10 to 30 nucleotides, then 10 and 30 nucleotides are included.

[0313] In some embodiments, the contiguous nucleotide sequence thereof comprises or consists of 10 to 35 nucleotides in length, such as 10 to 30, such as 11 to 22, such as 12 to 20, such as 14 to 18 or 14 to 16 contiguous nucleotides in length.

[0314] In some embodiments, the contiguous nucleotide sequence comprises or consists of a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides. It is generally understood that an oligonucleotide cannot be shorter than a contiguous nucleotide sequence.

[0315] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises or consists of a sequence that is fully complementary to the target sequence RegA1-A80 or RegB1-B29 as provided in Tables 5 and 6, respectively.

[0316] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 10 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 7 to 164, e.g., SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0317] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 12 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 7 to 164, e.g., SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0318] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 13 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 7 to 164, e.g., SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0319] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 14 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 7 to 164, e.g., SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0320] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 15 contiguous nucleotides having at least 90% identity, such as 100% identity, to a sequence selected from SEQ ID NOs: 7 to 164, such as SEQ ID NOs 7–86, such as SEQ ID NO: 7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86. Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0321] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 16 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from the group consisting of SEQ ID NOs: 7 to 164, e.g., SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0322] In some embodiments, an oligonucleotide of the invention or a contiguous nucleotide sequence thereof comprises at least 17 contiguous nucleotides having at least 90% identity, e.g., 100% identity, to a sequence selected from SEQ ID NOs: 65, 66, 71, 74 and 75 (see the motif sequences listed in Tables 7 and 8). Advantageously, the sequence is complementary to that of humans and cynomolgus monkeys, for example a sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84 and 85.

[0323] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0324] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0325] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 12 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0326] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 12 contiguous nucleotides that are at least 90% complementary, e.g., completely complementary, to a sequence selected from SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285 The group consisting of 4,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320 and 321.

[0327] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 13 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0328] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 13 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0329] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 14 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0330] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 14 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0331] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 15 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0332] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 15 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0333] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 16 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0334] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence comprises at least 16 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0335] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence is at least 90% complementary, e.g., completely complementary, to a sequence selected from the group consisting of SEQ ID NOs 167-246, e.g., SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 06, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences present in both humans and cynomolgus monkeys, for example selected from SEQ IDNO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183, 184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,2 02,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0336] In some embodiments of the invention, the oligonucleotide of the invention or its contiguous nucleotide sequence is at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NOs 247-326, e.g., SEQ ID NOs: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283 ,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320 and 321.

[0337] In some embodiments of the invention, the target sequence is selected from the group consisting of: SEQ ID Nos 167-246, such as SEQ ID NOs: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218 6, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246. Advantageously, targeting sequences that are present in both humans and cynomolgus monkeys, for example selected from SEQ ID NO: 167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,1 84,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,20 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,22 The sequence of 3,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0338] In some embodiments of the invention, the target sequence is selected from the group consisting of SEQ ID No 247-326, such as SEQ ID NO: 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320 and 321.

[0339] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are fully complementary to a region of a target nucleic acid, such as a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0340] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 12 contiguous nucleotides that are fully complementary to a region of a target nucleic acid, such as a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0341] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 13 contiguous nucleotides that are fully complementary to a region of a target nucleic acid, such as a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0342] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 14 contiguous nucleotides that are fully complementary to a region of a target nucleic acid, such as a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0343] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 15 contiguous nucleotides that are fully complementary to a region of a target nucleic acid, such as a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0344] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 16, e.g., at least 17, contiguous nucleotides that are fully complementary to a region of a target nucleic acid, e.g., a target sequence selected from the group consisting of SEQ ID NOs 222, 225, 226, 231, 234, and 235.

[0345] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises at least 16, e.g., at least 17, contiguous nucleotides that are fully complementary to a region of a target nucleic acid, the region of the target nucleic acid being from position 21084 to 21101 (region A59, Table 5), position 21214-21231 (region A60 Table 5), position 23806 to 23822 (region A70 Table 5), position 24060 to 24077 (region A68 Table 5), or position 24045 to 24098 (region A67-A70 Table 5) of SEQ ID NO: 1. In some embodiments, the oligonucleotide comprises or consists of a contiguous nucleotide sequence having 100% identity to a sequence selected from the group consisting of: SEQ ID NO 7-86, e.g., SEQ ID NO: 7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27, 28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0346] In some embodiments, the oligonucleotide comprises or consists of a contiguous nucleotide sequence selected from the group consisting of: SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0347] In some embodiments, the antisense oligonucleotide comprises or consists of a contiguous nucleotide sequence having 100% identity to a sequence selected from the group consisting of: SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0348] In some embodiments, the antisense oligonucleotide comprises or consists of a contiguous nucleotide sequence selected from the group consisting of: SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0349] In some embodiments, the antisense oligonucleotide comprises a contiguous nucleotide sequence having 100% identity to a sequence selected from the group consisting of SEQ ID NOs 65, 66, 71, 74, and 75, or at least 16 contiguous nucleotides thereof.

[0350] It will be appreciated that the contiguous nucleobase sequence (motif sequence) may be modified, for example, to increase nuclease resistance and / or binding affinity to a target nucleic acid.

[0351] The pattern of incorporating modified nucleosides (eg, high affinity modified nucleosides) into an oligonucleotide sequence is often referred to as oligonucleotide design.

[0352] The oligonucleotides of the present invention are designed using modified nucleosides and DNA nucleosides. Advantageously, high affinity modified nucleosides are used.

[0353] In one embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides. In one embodiment, the oligonucleotide comprises 1 to 10 modified nucleosides, such as 2 to 9 modified nucleosides, such as 3 to 8 modified nucleosides, such as 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides. Suitable modifications are described in the "modified nucleosides", "high affinity modified nucleosides", "sugar modifications", "2' sugar modifications" and "locked nucleic acids" (LNA) in the "definition" section.

[0354] In one embodiment, the oligonucleotide comprises one or more sugar-modified nucleosides, such as 2' sugar-modified nucleosides. Preferably, the oligonucleotide of the present invention comprises one or more 2' sugar-modified nucleosides, and the 2' sugar-modified nucleosides are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides. It is advantageous if one or more modified nucleosides are locked nucleic acids (LNA).

[0355] In further embodiments, the oligonucleotide comprises at least one modified internucleoside bond. Suitable internucleoside modifications are described in the "modified internucleoside bond" of the "definition" section. It is advantageous if at least 75% (e.g., all) of the internucleoside bonds in the continuous nucleotide sequence are phosphorothioate or boranophosphate (boranophosphate) internucleoside bonds. In some embodiments, all internucleoside bonds in the continuous sequence of an oligonucleotide are phosphorothioate bonds.

[0356] In some embodiments, the oligonucleotides of the invention comprise at least one LNA nucleoside, such as 1, 2, 3, 4, 5, 6, 7 or 8 LNA nucleosides, such as 2 to 6 LNA nucleosides, such as 3 to 7 LNA nucleosides, 4 to 8 LNA nucleosides or 3, 4, 5, 6, 7 or 8 LNA nucleosides. In some embodiments, at least 75% of the modified nucleosides in the oligonucleotide are LNA nucleosides, such as 80%, such as 85%, such as 90% of the modified nucleosides are LNA nucleosides. In further embodiments, all modified nucleosides in the oligonucleotide are LNA nucleosides. In further embodiments, the oligonucleotide may simultaneously comprise β-D-oxy-LNA and one or more of the following LNA nucleosides: β-D or α-L configuration thio-LNA, amino-LNA, oxy-LNA, ScET and / or ENA, or a combination thereof. In further embodiments, all LNA cytosine units are 5-methylcytosine. For the nuclease stability of an oligonucleotide or a continuous nucleotide sequence it is advantageous to have at least one LNA nucleoside at the 5' end of the nucleotide sequence and at least two LNA nucleosides at the 3' end of the nucleotide sequence.

[0357] In an embodiment of the invention, the oligonucleotide of the invention is capable of recruiting RNase H.

[0358] In the present invention, advantageous structural designs are gapmer designs as described in the "Definition" section, for example, in "Gapmer", "LNA Gapmer", "MOE gapmer" and "mixed wing gapmer" "alternating wing gapmer". Gapmer designs include gapmers with uniform flanks, mixed wing flanks, alternating flanks and gap break designs. In the present invention, it is advantageous if the oligonucleotide of the present invention is a gapmer with a FG-F' design. In some embodiments, the gapmer is an LNA gapmer, wherein at least one or both of regions F and F' comprise at least one LNA unit.

[0359] In some embodiments, the oligonucleotides of the invention do not comprise 6'-methyl-β-D-oxy-LNA nucleosides. In some embodiments, the oligonucleotides of the invention do not comprise 2'-O-methoxyethyl nucleosides.

[0360] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence having 100% identity to a sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0361] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 12 consecutive nucleotides thereof.

[0362] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 13 consecutive nucleotides thereof.

[0363] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 14 consecutive nucleotides thereof.

[0364] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 15 consecutive nucleotides thereof.

[0365] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 7-86, e.g., SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 and 86, or at least 16 consecutive nucleotides thereof.

[0366] In some embodiments, the LNA gapmer comprises or consists of a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs 65, 66, 71, 74 and 75, or at least 16 contiguous nucleotides thereof.

[0367] In some embodiments, the compound of the present invention comprises or consists of a contiguous nucleotide sequence selected from the group consisting of: SEQ ID NOs 7-86, for example, SEQ ID NOs: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 0,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85 and 86, wherein the design of the sequence corresponds to the sequence listed in Table 7. In particular, the flanks (F and F') are selected from 2'-sugar modified nucleosides (M), such as LNA, cET or MOE, and the gap constitutes a stretch of DNA (D). In a gapmer with an alternating flank design, the flanks of the oligonucleotide are annotated as a series of integers, representing a plurality of 2' sugar modified nucleosides (M) followed by a plurality of DNA nucleosides (D). For example, a flank with a 2-2-1 motif represents 5'[M]2-[D]2-[M]3', and a flank with a 1-1-1-1-1 motif represents 5'[M]-[D]-[M]-[D]-[M]3'. Both flanks have 2' sugar-modified nucleosides at the 5' and 3' ends. The gap region (G) consists of a number of DNA nucleosides (usually 5 to 16) located between the flanks.

[0368] In some embodiments, the compounds of the present invention comprise or consist of a contiguous nucleotide sequence selected from the group consisting of: CMP ID NO: 7_1-86_1, for example 7_1, 8_1, 9_1, 10_1, 11_1, 12_1, 13_1, 14_1, 15_1, 16_1, 17_1, 18_1, 19_1, 20_1, 21_1, 22_1, 23_1, 24_1, 25_1, 26_1, 27_1, 28_1, 29_1, 30_1, 31_1, 32_1, 33_1, 34_1, 35_1, 36_1, 37_1, 38_1, 39_1, 40_1, 41_1, 42_1, 43_1, 44_1, 45_1, 46_1, 47_1, 48_1, 49_1, 50_1, 51_1, 52_ 1,53_1,54_1,55_1,56_1,57_1,58_1,59_1,60_1,61_1,62_1,63_1,64_1,65_1,66_1,67_1,68_1,69_1,70_1,71_1,72_1,73_1,74_1,75_1,76_1,77_1,78_1,79_1,80_1,81_1,82_1,83_1,84_1,85_1 and 86_1, wherein uppercase letters are LNA nucleosides, lowercase letters are DNA nucleosides, LNA cytosine nucleosides are optionally 5-methylcytosine LNA, and DNA cytosine is optionally 5-methylcytosine DNA.

[0369] In some embodiments, the compound of the present invention comprises or consists of a contiguous nucleotide sequence selected from the group consisting of: CMP-ID-NO: 7_1-86_1, for example 7_1, 8_1, 9_1, 10_1, 11_1, 12_1, 13_1, 14_1, 15_1, 16_1, 17_1, 18_1, 19_1, 20_1, 21_1, 22_ 1,23_1,24_1,25_1,26_1,27_1,28_1,29_1,30_1,31_1,32_1,33_1,34_1,35_1,36_1,37_1,38_1,39_1,40_1,41_1,42_1,43_1,44_1,45_1,46_1,47_1,48_1,49_1,50_ 1,51_1,52_1,53_1,54_1,55_1,56_1,57_1,58_1,59_1,60_1,61_1,62_1,63_1,64_1,65_1,66_1,67_1,68_1,69_1,70_1,71_1,72_1,73_1,74_1,75_1,76_1,77_1,78 _1, 79_1, 80_1, 81_1, 82_1, 83_1, 84_1, 85_1 and 86_1, wherein uppercase letters are LNA nucleosides, lowercase letters are DNA nucleosides, LNA cytosine nucleosides are optionally 5-methylcytosine LNA, DNA cytosine is optionally 5-methylcytosine DNA, and the internucleoside bonds between all nucleosides in the consecutive nucleotide sequence are phosphorothioate internucleoside bonds.

[0370] In some embodiments, the compound of the present invention comprises or consists of a contiguous nucleotide sequence selected from the group consisting of: CMP-ID-NO: 7_1-86_1, for example 7_1, 8_1, 9_1, 10_1, 11_1, 12_1, 13_1, 14_1, 15_1, 16_1, 17_1, 18_1, 19_1, 20_1, 21_1, 2 2_1,23_1,24_1,25_1,26_1,27_1,28_1,29_1,30_1,31_1,32_1,33_1,34_1,35_1,36_1,37_1,38_1,39_1,40_1,41_1,42_1,43_1,44_1,45_1,46_1,47_1,48_1,49_ 1,50_1,51_1,52_1,53_1,54_1,55_1,56_1,57_1,58_1,59_1,60_1,61_1,62_1,63_1,64_1,65_1,66_1,67_1,68_1,69_1,70_1,71_1,72_1,73_1,74_1,75_1,76_1, 77_1, 78_1, 79_1, 80_1, 81_1, 82_1, 83_1, 84_1, 85_1 and 86_1, wherein the capital letters are β-D-oxy LNA nucleosides, the lowercase letters are DNA nucleosides, the LNA cytosine nucleoside is 5-methylcytosine LNA, and the internucleoside bonds between all nucleosides in the consecutive nucleotide sequence are phosphorothioate internucleoside bonds, as shown in Table 7.

[0371] In some embodiments, the compound of the present invention is selected from the group consisting of: CMP-ID-NO: 7_1-86_1, 7_1, 8_1, 9_1, 10_1, 11_1, 12_1, 13_1, 14_1, 15_1, 16_1, 17_1, 18_1, 19_1, 20_1, 21_1, 22_1, 23_1, 24_1, 25_1,26_1,27_1,28_1,29_1,30_1,31_1,32_1,33_1,34_1,35_1,36_1,37_1,38_1,39_1,40_1,41_1,42_1,43_1,44_1,45_1,46_1,47_1,48_1,49_1,50_1,51_1 ,52_1,53_1,54_1,55_1,56_1,57_1,58_1,59_1,60_1,61_1,62_1,63_1,64_1,65_1,66_1,67_1,68_1,69_1,70_1,71_1,72_1,73_1,74_1,75_1,76_1,77_1,78_ 1,79_1,80_1,81_1,82_1,83_1,84_1,85_1 and 86_1, wherein uppercase letters are LNA nucleosides, lowercase letters are DNA nucleosides, LNA cytosine nucleosides are optionally 5-methylcytosine LNA, DNA cytosine is optionally 5-methylcytosine DNA, and the internucleoside bonds between DNA nucleosides are phosphorothioate internucleoside bonds.

[0372] In some embodiments, the compounds of the present invention are selected from the group consisting of:

[0373] ATGTttatcaccaaAATT(SEQ ID NO:65,CMP ID NO:65_1)

[0374] CTGAaatactaccaTATA(SEQ ID NO:66,CMP ID NO:66_1)

[0375] TTTAatcataccaATCT(SEQ ID NO:71,CMP ID NO:71_1)

[0376] TTCTtatttcaaatCTCA(SEQ ID NO:74,CMP ID NO:74_1)

[0377] TCTTatttcaaatCTCA(SEQ ID NO:75,CMP ID NO:_1)

[0378] Wherein capital letters are LNA nucleosides, such as β-D-oxy-LNA, lowercase letters are DNA nucleosides, LNA cytosine nucleosides are optionally 5-methylcytosine LNA, DNA cytosine nucleosides are optionally 5-methylcytosine DNA, and the internucleoside bonds between DNA nucleosides are phosphorothioate internucleoside bonds.

[0379] In some embodiments, the compounds of the present invention are selected from the group of CMP-ID-NO:7_1-86_1 compounds, wherein the uppercase letters are LNA nucleosides, the lowercase letters are DNA nucleosides, the LNA cytosine nucleosides are optionally 5-methylcytosine LNA, the DNA cytosine is optionally 5-methylcytosine DNA, and all internucleoside bonds between nucleosides are phosphorothioate internucleoside bonds.

[0380] Advantageously, the compounds of the invention are in the form of pharmaceutically acceptable salts.

[0381] In a further embodiment of the invention, the oligonucleotide may comprise at least one stereo-defined internucleoside bond, such as a stereo-defined phosphorothioate internucleoside bond. The advantage of producing stereo-defined oligonucleotide variants is the ability to increase the diversity of the entire sequence motif, and to select stereo-defined oligonucleotides of a sub-library comprising stereo-defined oligonucleotides, which have improved medicinal chemistry properties compared to non-stereo-defined oligonucleotides.

[0382] The invention provides a conjugate comprising an oligonucleotide or antisense oligonucleotide according to the invention and at least one conjugate moiety covalently attached to the oligonucleotide. In some embodiments, the conjugate moiety is a conjugate that facilitates delivery across the blood-brain barrier, such as an antibody or antibody fragment targeting the transferrin receptor.

[0383] The present invention provides pharmaceutically acceptable salts of the oligonucleotide or antisense oligonucleotide or conjugate of the present invention.

[0384] In some embodiments, the contiguous nucleotide sequence of the present invention does not include 10 or more contiguous nucleotides present in the sequence GATCAGAGATTAAGGCCAA (SEQ ID NO 322). In some embodiments, the contiguous nucleotide sequence of the present invention does not include 10 or more contiguous nucleotides present in the sequence GCAGATTGATTATACGGTA (SEQ ID NO 323) or GTGGAAGGAACACGACTTA (SEQ ID NO 324).

[0385] Preparation method

[0386] In a further aspect, the invention provides a method for preparing the oligonucleotide of the present invention, the method comprising reacting nucleotide units and forming the covalently linked continuous nucleotide units contained in the oligonucleotide. Preferably, the method uses phosphoramidite chemistry (see, for example, Caruthers et al., 1987, Methods in Enzymology, Vol. 154, pp. 287-313). In a further embodiment, the method further comprises reacting the continuous nucleotide sequence with a conjugated moiety (ligand) to covalently attach the conjugate moiety to the oligonucleotide. In a further aspect, a method for preparing the composition of the present invention is provided, the method comprising mixing the oligonucleotide of the present invention or the conjugated oligonucleotide with a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0387] Medicinal salt

[0388] Compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to conventional acid addition salts or base addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed by suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid addition salts include, for example, those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, aminosulfonic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, etc. Base addition salts include those derived from ammonium hydroxide, potassium, sodium and quaternary ammonium salts, such as tetramethylammonium hydroxide. Chemical modification of pharmaceutical compounds into salts is a well-known technique for pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, fluidity and solubility of compounds. It is described, for example, in Bastin, Organic Process Research & Development 2000, 4, 427-435 or in Ansel, In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th edition (1995), pages 196 and 1456-1457. For example, a pharmaceutically acceptable salt of a compound provided herein may be a sodium salt.

[0389] In a further aspect, the present invention provides a pharmaceutically acceptable salt of the antisense oligonucleotide or its conjugate. In a preferred embodiment, the pharmaceutically acceptable salt is a sodium or potassium salt.

[0390] Pharmaceutical composition

[0391] In a further aspect, the present invention provides a pharmaceutical composition comprising any of the above oligonucleotides and / or oligonucleotide conjugates or salts thereof and a pharmaceutically acceptable diluent, carrier, salt and / or adjuvant. Pharmaceutically acceptable diluents include phosphate buffered saline (PBS), and pharmaceutically acceptable salts include but are not limited to sodium salts and potassium salts. In some embodiments, the pharmaceutically acceptable diluent is sterile phosphate buffered saline. In some embodiments, the oligonucleotide is used in a pharmaceutically acceptable diluent in a solution at a concentration of 50-300 μM.

[0392] Suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th edition, 1985. For a brief review of drug delivery methods, see, for example, Langer (Science 249: 1527-1533, 1990). WO 2007 / 031091 provides further suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (incorporated herein by reference). WO 2007 / 031091 also provides suitable dosages, formulations, routes of administration, compositions, dosage forms, combinations with other therapeutic agents, and prodrug formulations.

[0393] The oligonucleotide or oligonucleotide conjugate of the present invention can be mixed with a pharmaceutically acceptable active or inert substance to prepare a pharmaceutical composition or formulation. The components and methods of formulating a pharmaceutical composition depend on many criteria, including but not limited to the route of administration, the extent of the disease or the dosage of administration.

[0394] These compositions can be sterilized by conventional sterilization techniques, or can be aseptically filtered. The resulting aqueous solution can be used directly or lyophilized after packaging, and the lyophilized preparation is mixed with a sterile aqueous carrier before application. The pH of the preparation is generally 3 to 11, more preferably 5 to 9 or 6 to 8, most preferably 7 to 8, such as 7 to 7.5. The resulting composition in solid form can be packaged in multiple single-dose units, each unit containing a fixed amount of one or more of the above-mentioned agents, such as in a sealed package of a tablet or capsule. The composition in solid form can also be packaged in a container with a flexible amount, such as in a squeezable tube designed for topical creams or ointments.

[0395] In some embodiments, the oligonucleotide or oligonucleotide conjugate of the present invention is a prodrug. In particular, for oligonucleotide conjugates, once the prodrug is delivered to the site of action, such as a target cell, the conjugate portion of the oligonucleotide is cleaved.

[0396] application

[0397] The oligonucleotides of the invention are useful as research reagents, for example for diagnosis, therapy and prevention.

[0398] In research, such oligonucleotides can be used to specifically regulate the synthesis of TMEM106B protein in cells (e.g., in vitro cell cultures) and experimental animals, thereby facilitating the functional analysis of the target or the evaluation of its use as a target for therapeutic intervention. Typically, target regulation is achieved by degrading or inhibiting the mRNA that produces the protein, thereby preventing protein formation, or by degrading or inhibiting regulators of the gene or mRNA that produces the protein.

[0399] If the oligonucleotides of the invention are employed in research or diagnostics, the target nucleic acid may be cDNA or a synthetic nucleic acid derived from DNA or RNA.

[0400] The present invention provides an in vivo or in vitro method for regulating TMEM106B expression in a target cell expressing TMEM106B, the method comprising administering an effective amount of an oligonucleotide of the present invention to the cell.

[0401] In some embodiments, the target cell is a neuronal cell. In some embodiments, the target cell is a microglia cell.

[0402] In some embodiments, the target cell is a mammalian cell, particularly a human cell. The target cell can be an in vitro cell culture or an in vivo cell that forms part of a tissue in a mammal. In a preferred embodiment, the target cell is present in the CNS, such as in the brain, such as in the frontotemporal lobe.

[0403] In some embodiments, the target cell is a CNS cell, a brain cell, a frontal cortex cell, or a frontotemporal cell.

[0404] In some embodiments, the target cell is a cell present in the thalamus, hippocampus, striatum, retina, or spinal cord.

[0405] In some embodiments, the target cell is a thalamic cell, a hippocampal cell, a striatal cell, a retinal cell, or a spinal cord cell.

[0406] It should be understood that for in vitro use, such as for evaluating TMEM106B expression or its inhibition, or targeting in a cell (e.g., a target cell), the cell can be isolated from a tissue or can be derived from a tissue (e.g., an established or immortalized cell line), such as CNS tissue, brain tissue, frontal cortex, frontotemporal lobe tissue, thalamus tissue, hippocampus tissue, striatum tissue, retinal tissue, or spinal cord tissue. Cells isolated from target tissues are referred to as primary cells.

[0407] In diagnostics, the oligonucleotides can be used to detect and quantify TMEM106B expression in cells and tissues by northern blot, in situ hybridization or similar techniques.

[0408] For therapy, the oligonucleotides can be administered to an animal or human suspected of having a disease or condition that can be treated by modulating the expression of TMEM106B.

[0409] The present invention provides a method for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the present invention to a subject suffering from or susceptible to the disease.

[0410] The invention also relates to an oligonucleotide, composition or conjugate as defined herein for use as a medicament.

[0411] The oligonucleotide, oligonucleotide conjugate or pharmaceutical composition according to the present invention is generally administered in an effective amount.

[0412] The present invention also provides use of an oligonucleotide or oligonucleotide conjugate of the present invention as described in the preparation of a medicament for treating a disorder described herein, or use in a method for treating a disorder described herein.

[0413] As indicated herein, the disease or disorder is associated with the expression of TMEM106B. In some embodiments, the disease or disorder may be associated with a mutation in a TMEM106B gene or a gene whose protein product is associated with or interacts with TMEM106B. Therefore, in some embodiments, the target nucleic acid is a mutant form of a TMEM106B sequence, and in other embodiments, the target nucleic acid is a regulator of a TMEM106B sequence.

[0414] The method of the present invention is preferably used to treat or prevent a disease caused by abnormal levels and / or activity of TMEM106B.

[0415] The present invention further relates to the use of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition as defined herein for the preparation of a medicament for treating abnormal levels and / or activity of TMEM106B.

[0416] In some aspects, the present invention relates to an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the present invention for use in treating a disease or condition selected from the group consisting of neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0417] In some embodiments, compounds of the invention are used to treat age-related changes in the frontal cortex.

[0418] In one aspect, the present invention relates to an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the present invention for use in the treatment of frontotemporal lobar degeneration (FTLD). The oligonucleotide, oligonucleotide conjugate or pharmaceutical composition may be advantageous in the treatment of FTLD characterized by nuclear and / or cytoplasmic accumulation of ubiquitinated proteins (FTLD-U), in particular, FTDL-TDP and other TDP-43 proteinopathies characterized by accumulation of ubiquitinated TAR DNA binding protein 43 (TDP-43) in the frontal and temporal brain regions.

[0419] Application

[0420] The oligonucleotide or pharmaceutical composition of the present invention can be administered parenterally (eg, intravenously, subcutaneously, intramuscularly, intracerebrally, intracerebroventricularly, intraocularly or intrathecally).

[0421] In some embodiments, administration is by intrathecal administration.

[0422] Advantageously, for example for the treatment of neurological disorders, the oligonucleotide or pharmaceutical composition of the invention is administered intrathecally or intracranially, for example intracerebrally or intraventricularly.

[0423] The present invention also provides the use of an oligonucleotide or a conjugate thereof, such as a pharmaceutically acceptable salt or composition of the present invention, in the preparation of a medicament, wherein the medicament is in a dosage form for subcutaneous administration.

[0424] The present invention also provides use of the oligonucleotide of the present invention or its conjugate, such as the pharmaceutically acceptable salt or composition of the present invention, in the preparation of a medicament, wherein the medicament is a dosage form for intrathecal administration.

[0425] Combination therapy

[0426] In some embodiments, the oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions of the invention are used in combination therapy with another therapeutic agent. The therapeutic agent may be, for example, the standard of care for the above-mentioned diseases or conditions.

[0427] Implementation

[0428] 1. An oligonucleotide targeting TMEM106B, comprising a continuous nucleotide sequence of 10-30 nucleotides in length that is at least 90% complementary to a mammalian TMEM106B target nucleic acid, such as completely complementary.

[0429] 2. The oligonucleotide according to embodiment 1, wherein the oligonucleotide is capable of reducing the expression of a mammalian TMEM106B target nucleic acid in a cell.

[0430] 3. The oligonucleotide according to any one of embodiments 1 to 2, wherein the oligonucleotide is a therapeutic oligonucleotide.

[0431] 4. The oligonucleotide according to any one of embodiments 1 to 3, wherein the mammalian TMEM106B target nucleic acid is selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5 and 6, or a naturally occurring variant thereof.

[0432] 5. The oligonucleotide of embodiment 4, wherein the naturally occurring variant is selected from the polymorphisms listed in Table 4.

[0433] 6. The oligonucleotide of embodiments 1 to 5, wherein the target nucleic acid is RNA.

[0434] 7. The oligonucleotide of embodiment 6, wherein the RNA is mRNA.

[0435] 8. The oligonucleotide of embodiment 7, wherein the mRNA is a pre-RNA or a mature RNA.

[0436] 9. An oligonucleotide according to any one of embodiments 1 to 8, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 7,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245 and 246, or the group consisting of SEQ ID NO: 247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,2 65,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,28 The group consisting of 4,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320 and 321.

[0437] 10. The oligonucleotide according to any one of embodiments 1 to 9, wherein the oligonucleotide or contiguous nucleotide sequence is fully complementary to SEQ ID NO: 1 and / or 2 or a naturally occurring variant thereof.

[0438] 11. An oligonucleotide according to any one of embodiments 1 to 10, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, such as fully complementary, to a region of SEQ ID NO 1, wherein the region is selected from the group consisting of SEQ ID NO 1 position 546-563; 2122-2140; 2143-2160; 2165-2183; 2300-2317; 2392-2410; 2548-2565; 3507-3524; 3678-3694; 3736-3753; 3752-3767; 3802-3819; 3908-3925; 3908-6417; 4321-4337; 4701-4720; 4948-4965; 5063-5080; 5069-5086; 5172-5190; 5512-5530; 5583-5599; 60 15-6047; 6015-6032; 6032-6047; 6125-6154; 6125-6140; 6136-6154; 6172-6189; 6200-6231; 6200-6216; 6214-6231; 6401-6417; 6458-6476; 6837-6853; 8453-8472; 8983-9001; 9533-9549; 9628-9644; 11065-11083; 11117-11134; 11264-11281; 12310-12325; 12870-12 887; 13050-13065; 13397-13414; 15061-15079; 15249-15266; 15318-15336; 15368-15385; 15440-15457; 15632-15649; 15823-15842; 16496-16513; 19090-19109; 19198-19217; 19211-19228; 19699-19718; 20217-20243; 20217-20236; 20227-20243; 20755-26403; 2076 7-20786; 20880-20896; 21084-21101; 21214-21231; 21425-21442; 22110-25406; 22110-22128; 23374-23393; 23435-23452; 23806-23822; 23874-23890; 24045-24098; 24045-24063; 24060-24077; 24060-24076; 24064-24083; 24081-24098; 24045-24098; 24801-24828;The group consisting of 24801-24819; 24812-24828; 25050-25067; 25372-25387; 25392-25406; 25773-25790; 25796-25814; 25969-25985; and 29351–29367. ;

[0439] 12. An oligonucleotide according to any one of embodiments 1 to 11, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206 ,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245 and 246.

[0440] 13. The oligonucleotide according to any one of embodiments 1 to 12, wherein the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO: 1 and SEQ ID NO: 3 or naturally occurring variants thereof.

[0441] 14. The oligonucleotide according to embodiment 13, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides that are at least 90% complementary, e.g., fully complementary, to a sequence selected from the group consisting of SEQ ID NO: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 The group consisting of 2,203,204,206,208,209,210,211,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,229,230,231,232,236,237,238,239,240,241,243,244 and 245.

[0442] 15. The oligonucleotide of any one of embodiments 1 to 14, comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length having at least 90% complementarity, such as complete complementarity, to the 3'UTR of a mammalian TMEM106B target nucleic acid.

[0443] 16. The oligonucleotide of any one of embodiments 1 to 15, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary, such as fully complementary, to the sequence at positions 20227 to 26403 or positions 20227-24077 of SEQ ID NO 1.

[0444] 17. The oligonucleotide of any one of embodiments 1 to 16, wherein the contiguous nucleotide sequence is at least 90% complementary to positions 20755 to 26403 of SEQ ID NO 1, such as fully complementary.

[0445] 18. The oligonucleotide of any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary, e.g., fully complementary, to the sequence at positions 21084 to 21231, e.g., positions 21084 to 21213, of SEQ ID NO 1.

[0446] 19. The oligonucleotide of any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary to positions 22110 to 25406 of SEQ ID NO 1, such as fully complementary.

[0447] 20. The oligonucleotide of any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary to positions 23086 to 24077 of SEQ ID NO 1, such as fully complementary.

[0448] 21. The oligonucleotide of any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary to positions 20227 to 20243 of SEQ ID NO 1, such as fully complementary.

[0449] 22. The oligonucleotide of any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary to positions 20227 to 26403 of SEQ ID NO 1, such as fully complementary.

[0450] 23. The present invention provides an oligonucleotide targeting TMEM106B, which comprises a contiguous nucleotide sequence of at least 10 nucleotides in length that is at least 90% complementary, for example, completely complementary, to positions 24045 to 24098 of SEQ ID NO 1.

[0451] 24. An oligonucleotide according to any one of embodiments 1 to 17, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary, e.g., fully complementary, to the following region, the region being selected from the group consisting of positions 22110-22128, 24045-24063, 24060-24077, 24812-24828 and 25392-25406 of SEQ ID NO1.

[0452] 25. The oligonucleotide according to any one of embodiments 1 to 14, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary, such as fully complementary, to positions 3908-6417 of SEQ ID NO 1.

[0453] 26. An oligonucleotide according to embodiment 25, wherein the contiguous nucleotide sequence of at least 10 nucleotides in length is at least 90% complementary, e.g., fully complementary, to the following region, the region being selected from the group consisting of positions 3908-3925, 6136-6154, 5172-5190, 6200-6216 and 6401-6417 of SEQ ID NO: 1.

[0454] 27. The oligonucleotide according to any one of embodiments 1 to 26, wherein the contiguous nucleotide sequence is fully complementary to SEQ ID NO: 1 or one of the SEQ ID NOs listed in embodiment 12 or 14.

[0455] 28. The oligonucleotide according to any one of embodiments 1 to 27, wherein the oligonucleotide is capable of hybridizing to a target nucleic acid of SEQ ID NO: 1 or a target sequence selected from the group consisting of: SEQ ID NO: 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206 06, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 and 246.

[0456] 29. An oligonucleotide according to any one of embodiments 1 to 28, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides, such as at least 12 or at least 14 contiguous nucleotides present in the following sequence, the sequence being selected from SEQ ID NO: 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86.

[0457] 30. The oligonucleotide of any one of embodiments 1 to 29, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides selected from the group consisting of: SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 76, 77, 78, 79, 80, 81, 83, 84, and 85.

[0458] 31. The oligonucleotide according to any one of embodiments 1 to 9, wherein the contiguous nucleotide sequence comprises at least 10 contiguous nucleotides selected from the group consisting of: SEQ ID NO: 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125 ,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160 and 161.

[0459] 32. An oligonucleotide according to any one of embodiments 1 to 31, wherein the oligonucleotide is shorter than 60 nucleotides in length, for example shorter than 50 nucleotides in length, such as 10 to 60 or 10 to 50 nucleotides in length.

[0460] 33. The oligonucleotide of embodiments 1-32, wherein the contiguous nucleotide sequence comprises or consists of at least 10 contiguous nucleotides, in particular 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 contiguous nucleotides.

[0461] 34. An oligonucleotide according to embodiment 33, wherein the contiguous nucleotide sequence is at least 12 nucleotides in length, such as at least 14 nucleotides in length, and the nucleotides are fully complementary to SEQ ID NO 1 or one of the SEQ ID NOs listed in embodiment 12 or 14.

[0462] 35. The oligonucleotide according to any one of embodiments 1 to 32, wherein the contiguous nucleotide sequence comprises or consists of 12 to 22 nucleotides.

[0463] 36. The oligonucleotide of embodiment 35, wherein the contiguous nucleotide sequence comprises or consists of 14-20 nucleotides.

[0464] 37. An oligonucleotide according to any one of embodiments 1 to 36, wherein the contiguous nucleotide sequence has zero to three mismatches compared to the target nucleic acid to which it is complementary.

[0465] 38. The oligonucleotide of embodiment 37, wherein the contiguous nucleotide sequence has one mismatch compared to the target nucleic acid.

[0466] 39. The oligonucleotide of embodiment 37, wherein the contiguous nucleotide sequence has two mismatches compared to the target nucleic acid.

[0467] 40. The oligonucleotide of embodiment 37, wherein the contiguous nucleotide sequence is completely complementary to the target nucleic acid sequence.

[0468] 41. The oligonucleotide according to any one of embodiments 1 to 40, wherein the oligonucleotide comprises one or more 2' sugar modified nucleosides.

[0469] 42. An oligonucleotide according to embodiment 41, wherein the one or more 2' sugar modified nucleosides are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.

[0470] 43. The oligonucleotide of embodiment 42, wherein at least one of the one or more 2' sugar modified nucleosides is an LNA nucleoside.

[0471] 44. An oligonucleotide according to embodiment 43, wherein the modified LNA nucleoside is selected from oxy-LNA, amino-LNA, thio-LNA, cET and ENA.

[0472] 45. An oligonucleotide according to embodiment 43 or 44, wherein the modified LNA nucleoside is an oxy-LNA having the following 2'-4' bridge -O-CH2-.

[0473] 46. ​​The oligonucleotide of embodiment 45, wherein the oxy-LNA is β-D-oxy-LNA.

[0474] 47. An oligonucleotide according to embodiment 43 or 44, wherein the modified LNA nucleoside is cET with the following 2′-4′ bridge -O—CH(CH 3 )—.

[0475] 48. The oligonucleotide of embodiment 47, wherein the cET is (S)cET, ie, 6'(S)methyl-β-D-oxy-LNA.

[0476] 49. The oligonucleotide according to embodiment 43 or 44, wherein the LNA is an ENA with the following 2′–4′ bridge: —O—CH2-CH2—.

[0477] 50. The oligonucleotide of any one of embodiments 1-49, wherein the contiguous nucleotide sequence comprises at least one modified internucleoside bond.

[0478] 51. An oligonucleotide according to any one of embodiments 1-50, wherein the contiguous nucleotide sequence comprises at least one phosphorothioate modified internucleoside bond.

[0479] 52. The oligonucleotide according to any one of embodiments 1 to 51, wherein the oligonucleotide is a siRNA or shRNA or a guide strand that forms a siRNA or shRNA complex.

[0480] 53. The oligonucleotide of embodiment 52, wherein the oligonucleotide is a double-stranded siRNA oligonucleotide or shRNA oligonucleotide capable of interacting with the RISC complex.

[0481] 54. The oligonucleotide according to any one of embodiments 1 to 51, wherein the oligonucleotide is an antisense oligonucleotide.

[0482] 55. The antisense oligonucleotide of embodiment 54, wherein the oligonucleotide is single-stranded.

[0483] 56. The oligonucleotide of embodiment 54 or 55, wherein at least 75% or all of the internucleoside bonds between nucleosides of the contiguous nucleotide sequence are phosphorothioate internucleoside bonds.

[0484] 57. An oligonucleotide according to any one of embodiments 54 to 56, wherein the oligonucleotide is capable of recruiting RNase H1.

[0485] 58. The antisense oligonucleotide of embodiment 57, wherein the oligonucleotide is an antisense oligonucleotide gapmer.

[0486] 59. An antisense oligonucleotide according to embodiment 57 or 58, wherein the antisense oligonucleotide or its contiguous nucleotide sequence consists of or comprises a gapmer of formula 5'-FG-F'-3', wherein regions F and F' independently comprise 1-8 nucleosides, 1-5 of which are independently 2' sugar modified and define the 5' and 3' ends of the F and F' regions, and G is a region of 5 to 18 nucleosides capable of recruiting RNaseH, such as a region comprising 5-18 DNA nucleosides.

[0487] 60. The antisense oligonucleotide of embodiment 59, wherein the 2′ sugar modified nucleosides are independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides.

[0488] 61. The antisense oligonucleotide of embodiment 59 or 60, wherein one or more 2' sugar modified nucleosides in the F and F' regions are LNA nucleosides.

[0489] 62. An antisense oligonucleotide according to any one of embodiments 60 or 61, wherein the LNA nucleoside is selected from β-D-oxy-LNA, α-L-oxy-LNA, β-D-amino-LNA, α-L-amino-LNA, β-D-thio-LNA, α-L-thio-LNA, (S)cET, (R)cET β-D-ENA and α-L-ENA.

[0490] 63. The antisense oligonucleotide according to any one of embodiments 54 to 62, wherein the antisense oligonucleotide is selected from the group consisting of LNA gapmers, mixed-wing gapmers and alternating-wing gapmers.

[0491] 64. The oligonucleotide of embodiments 59-63, wherein

[0492] The aF region is 1 to 5 nucleotides in length and consists of 1-4 identical LNA nucleosides and 0-2 DNA nucleosides; and

[0493] The bF′ region is 2 to 5 nucleotides in length and consists of 2-4 identical LNA nucleosides and 0-2 DNA nucleosides; and

[0494] c. Region G is 8 to 16 DNA nucleotides.

[0495] 65. The antisense oligonucleotide of embodiments 59 to 62, wherein regions F and F′ consist of the same LNA nucleoside.

[0496] 66. The antisense oligonucleotide of embodiments 59 to 62, wherein all 2' sugar modified nucleosides in regions F and F' are oxy-LNA nucleosides.

[0497] 67. The antisense oligonucleotide of any one of embodiments 54 to 60, wherein the antisense oligonucleotide is a 2′-MOE gapmer.

[0498] 68. The antisense oligonucleotide of any one of embodiments 54 to 67, wherein the nucleosides in region G are DNA and / or α-L-LNA nucleosides.

[0499] 69. The antisense oligonucleotide of embodiment 68, wherein region G consists of at least 75% DNA nucleosides.

[0500] 70. The antisense oligonucleotide of embodiment 69, wherein all nucleosides in region G are DNA nucleosides.

[0501] 71. An oligonucleotide according to any one of embodiments 1-51 or 54-70, wherein the oligonucleotide or its contiguous nucleotide sequence is selected from the motif sequences combined with the specified designs listed in Table 7.

[0502] 72. The oligonucleotide according to any one of embodiments 1-51 or 54-71, wherein the oligonucleotide or its contiguous nucleotide sequence is selected from the group consisting of: CMP ID as listed in Table 7 NO: 7_1,8_1,9_1,10_1,11_1,12_1,13_1,14_1,15_1,16_1,17_1,18_1,19_1,20_1,21_1,22_1,23_1,24_1,25_1,26_1,27_1 ,28_1,29_1,30_1,31_1,32_1,33_1,34_1,35_1,36_1,37_1,38_1,39_1,40_1,41_1,42_1,43_1,44_1,45_1,46_1,47_1,48_1 ,49_1,50_1,51_1,52_1,53_1,54_1,55_1,56_1,57_1,58_1,59_1,60_1,61_1,62_1,63_1,64_1,65_1,66_1,67_1,68_1,69_1,70_1,71_1,72_1,73_1,74_1,75_1,76_1,77_1,78_1,79_1,80_1,81_1,82_1,83_1,84_1,85_1,86_1,87_1,88_1,89_1,90_ 1,91_1,92_1,93_1,94_1,95_1,96_1,97_1,98_1,99_1,100_1,101_1,102_1,103_1,104_1,105_1,106_1,107_1,108_1,109_1,110_1,111_1,112_1,113_1,114_1,115_1,116_1,117_1,118_1,119_1,120_1,121_1,122_1,123_1,124_1,125_1,126_1, 127_1, 128_1, 129_1, 130_1, 131_1, 132_1, 133_1, 134_1, 135_1, 136_1, 137_1, 138_1, 139_1, 140_1, 141_1, 142_1, 143_1, 144_1, 145_1, 146_1, 147_1, 148_1, 149_1, 150_1, 151_1, 152_1, 153_1, 154_1, 155_1, 156_1, 157_1, 158_1, 159_1, 160_1 and 161_1.

[0503] 73. The oligonucleotide according to any one of embodiments 1-51 or 54-72, wherein the oligonucleotide or its contiguous nucleotide sequence is selected from the group consisting of:

[0504] ATGTttatcaccaaAATT(SEQ ID NO: 65,CMP ID NO: 65_1)

[0505] CTGAaatactaccaTATA(SEQ ID NO: 66, CMP ID NO: 66_1)

[0506] TTTAatcataccaATCT (SEQ ID NO: 71, CMP ID NO: 71_1)

[0507] TTCTtatttcaaatCTCA(SEQ ID NO:74,CMP ID NO:74_1)

[0508] TCTTatttcaaatCTCA(SEQ ID NO:75,CMP ID NO:_1)

[0509] Wherein capital letters are LNA nucleosides, such as β-D-oxy-LNA, lowercase letters are DNA nucleosides, LNA cytosine nucleosides are optionally 5-methylcytosine LNA, DNA cytosine nucleosides are optionally 5-methylcytosine DNA, and the internucleoside bonds between DNA nucleosides are phosphorothioate internucleoside bonds.

[0510] 74. A conjugate comprising the oligonucleotide or antisense oligonucleotide according to any one of embodiments 1-73, and at least one conjugate moiety covalently attached to the oligonucleotide.

[0511] 75. An oligonucleotide conjugate according to embodiment 74, wherein the conjugate moiety is selected from a carbohydrate, a cell surface receptor ligand, a drug, a hormone, a lipophilic substance, a polymer, a protein, a peptide, a toxin, a vitamin, a viral protein or a combination thereof.

[0512] 76. An oligonucleotide conjugate according to embodiment 74 or 75, wherein the conjugate promotes delivery across the blood-brain barrier.

[0513] 77. An oligonucleotide conjugate according to embodiment 76, wherein the conjugate is an antibody or antibody fragment targeting transferrin receptor.

[0514] 78. A pharmaceutically acceptable salt of the oligonucleotide or antisense oligonucleotide according to any one of embodiments 1-72 or the conjugate according to embodiments 74-77.

[0515] 79. A pharmaceutical composition comprising the oligonucleotide or antisense oligonucleotide of any one of embodiments 1-72 or the conjugate of embodiments 74-77 and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0516] 80. An in vitro or in vivo method for regulating TMEM106B expression in a target cell expressing TMEM106B, the method comprising administering to the cell an effective amount of an oligonucleotide or antisense oligonucleotide according to any one of embodiments 1-72, a conjugate according to embodiments 74-77, a pharmaceutically acceptable salt according to embodiment 78, or a pharmaceutical composition according to embodiment 79.

[0517] 81. A method for treating or preventing a disease, comprising administering to a subject suffering from or susceptible to the disease a therapeutically effective amount or a prophylactically effective amount of the oligonucleotide or antisense oligonucleotide of any one of embodiments 1-72, the conjugate of embodiments 74-77, or the pharmaceutically acceptable salt of embodiment 78, or the pharmaceutical composition of embodiment 79.

[0518] 82. The oligonucleotide or antisense oligonucleotide of any one of embodiments 1-72, the conjugate of embodiments 74-77, or the pharmaceutically acceptable salt of embodiment 78, or the pharmaceutical composition of embodiment 79, for use in a drug for treating or preventing a disease in a subject.

[0519] 83. An oligonucleotide or antisense oligonucleotide according to any one of embodiments 1 to 72, a conjugate according to embodiments 74-77, or a pharmaceutically acceptable salt according to embodiment 78, or a pharmaceutical composition according to embodiment 79, for use in the treatment or prevention of a disease selected from the group consisting of neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or parkinsonism), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0520] 84. Use of the oligonucleotide or antisense oligonucleotide according to any one of embodiments 1 to 72, the conjugate according to embodiments 74-77, the pharmaceutically acceptable salt according to embodiment 78, or the pharmaceutical composition according to embodiment 79 in the preparation of a medicament for treating or preventing a disease.

[0521] 85. The oligonucleotide for use, or the use or the method according to any one of embodiments 81 to 84, wherein the disease is associated with overexpression of TMEM106B and / or abnormal levels of TMEM106B.

[0522] 86. The oligonucleotide for use, or the use or the method according to any one of embodiments 81 to 84, wherein the treatment reduces TMEM106B mRNA levels in the frontal cortex to normal levels.

[0523] 87. The oligonucleotide for use, or the use or method according to any one of embodiments 81 to 84, wherein the disease is selected from the group consisting of: neurodegeneration, frontotemporal lobar degeneration (FTLD), Parkinson's disease (or Parkinson's syndrome), hypomyelinating leukodystrophy, amyotrophic lateral sclerosis and multiple system atrophy, Alzheimer's disease, motor neuron disease, corticobasal syndrome, progressive supranuclear palsy and neuronal ceroid lipofuscinosis (NCL).

[0524] 88. The oligonucleotide for use, or the use or the method according to any one of claims 81 to 87, wherein the disease is frontotemporal lobar degeneration (FTLD).

[0525] 89. The oligonucleotide for use or the use or the method according to any one of claims 81 to 84 to 88, wherein the subject is a mammal.

[0526] 90. The oligonucleotide for use or the use or the method according to embodiment 89, wherein the mammal is a human.

[0527] Example

[0528] Materials and methods

[0529] Oligonucleotide compounds and motif sequences

[0530] Table 7 – List of compounds

[0531] Listing of oligonucleotide motif sequences (represented by SEQ ID NO), their design and specific oligonucleotide compounds designed based on the motif sequences (represented by CMP ID NO).

[0532] In the Examples, the compounds used have the following structures: capital letters represent β-D-oxy LNA nucleosides; all LNA cytosines are 5-methylcytosine; lowercase letters represent DNA nucleosides; and all internucleoside bonds are phosphorothioate internucleoside bonds.

[0533]

[0534]

[0535]

[0536]

[0537]

[0538] The motif sequence represents the contiguous sequence of nucleobases present in an oligonucleotide.

[0539] Design refers to oligonucleotide design, for example, gapmer design FGF'. In a classic gapmer design such as 3-10-3, all nucleotides in the flanks (F and F') are composed of the same 2'-sugar-modified nucleosides such as LNA, cET or MOE, and a section of DNA in the middle that forms a gap (G). In a gapmer with an alternating flank design, the flanks of the oligonucleotide are annotated as a series of integers, representing multiple 2' sugar-modified nucleosides (M), followed by multiple DNA nucleosides (D). For example, a flank with a 2-2-1 motif represents 5'[M]2-[D]2-[M]3', and a flank with a 1-1-1-1-1 motif represents 5'[M]-[D]-[M]-[D]-[M]3'. Both flanks have 2' sugar-modified nucleosides at the 5' and 3' ends. The gap region (G) is composed of many DNA nucleosides (usually 5 to 16) located between the flanks.

[0540] The oligonucleotide compounds represent specific designs of motif sequences. Capital letters represent β-D-oxy LNA nucleosides, lower case letters represent DNA nucleosides, all LNA Cs are 5-methylcytosine, and all internucleoside bonds are phosphorothioate internucleoside bonds.

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549] Oligonucleotide synthesis

[0550] Oligonucleotide synthesis is well known in the art. The following is a possible applicable protocol. The oligonucleotides of the present invention can be produced by slightly varying methods with respect to the equipment, supports and concentrations used.

[0551] Oligonucleotides were synthesized on a uridine universal support using the phosphoramidite method on an Oligomaker 48 at a 1 μmol scale. At the end of the synthesis, the oligonucleotides were cleaved from the solid support using ammonia at 60°C for 5-16 hours. Oligonucleotides were purified by reverse phase HPLC (RP-HPLC) or by solid phase extraction and characterized by UPLC, and the molecular weight was further confirmed by ESI-MS.

[0552] Extension of oligonucleotides:

[0553] β-Cyanoethylphosphoramidite (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf) or LNA-T) coupling was performed by using 0.1 M 5′-O-DMT protected amidite in acetonitrile and DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as activators. For the final cycle, the phosphoramidite with the desired modification can be used, such as a C6 linker for attaching a conjugate group or such a conjugate group itself. Thiolation for the introduction of phosphorothioate bonds was performed by using hydridoxanthane (0.01 M in acetonitrile / pyridine 9:1). Phosphodiester bonds were introduced by using 0.02 M iodine in THF / pyridine / water 7:2:1. The remaining reagents are those commonly used for oligonucleotide synthesis.

[0554] For conjugation after solid phase synthesis, a commercially available C6 amino linker phosphoramidite can be used in the last cycle of solid phase synthesis, and after deprotection and cleavage from the solid support, the amino-linked deprotected oligonucleotide is isolated. The conjugate is introduced by activation of the functional group using standard synthetic methods.

[0555] Purification by RP-HPLC:

[0556] The crude compound was purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10μ1 50x10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile were used as buffers at a flow rate of 5 mL / min. The collected fractions were lyophilized to give the purified compound, typically as a white solid.

[0557] abbreviation:

[0558] DCI:4,5-Dicyanoimidazole

[0559] DCM: dichloromethane

[0560] DMF: Dimethylformamide

[0561] DMT:4,4'-Dimethoxytrityl

[0562] THF:Tetrahydrofuran

[0563] Bz: Benzoyl

[0564] Ibu: Isobutyryl

[0565] RP-HPLC: Reversed-Phase High-Performance Liquid Chromatography

[0566] T m Determination:

[0567] Dilute the oligonucleotide and RNA target (phosphate-linked, PO) duplex to 3 mM in 500 ml RNase-free water and mix with 500 ml 2x T m Buffer (200 mM NaCl, 0.2 mM EDTA, 20 mM sodium phosphate, pH 7.0) was mixed. The solution was heated to 95°C for 3 minutes and then annealed at room temperature for 30 minutes. The duplex melting temperature (T m ) was measured on a Lambda 40UV / VIS spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature was increased from 20°C to 95°C and then decreased to 25°C, and the absorption at 260nm was recorded. The duplex Tm was estimated using the first derivative and the local maxima of melting and annealing.

[0568] Example 1: In vitro reduction of TMEM106b in Neuro2a mouse cell line using oligonucleotides

[0569] LNA-modified oligonucleotides targeting mouse Tmem106b were tested for their ability to reduce Tmem106b mRNA expression in mouse Neuro-2a neuroblastoma cells obtained from ATCC (CCL-131).

[0570] Neuro2a cells were grown in cell culture medium (DMEM AQ medium [Sigma, cat. D0819] supplemented with 10% fetal bovine serum [Sigma, cat. no F7524], 1x GlutamaxTM [Sigma, cat. no 3050-038], 1 mM sodium pyruvate and 25 μg / ml gentamicin) at 37°C and 5% CO2 in a cell culture incubator. After reaching 80% confluence, the cells were trypsinized by washing with phosphate buffered saline (PBS) [Sigma cat. no 14190-094], then adding 0.25% trypsin-EDTA solution (Sigma, T3924), incubating at 37°C for 2-3 minutes, and grinding before cell seeding. The cells were kept in culture for up to 15 passages.

[0571] For experimental purposes, 2400 cells per well were seeded in 95 μL growth medium in a 96-well plate (Nunc cat. no 167008). Oligonucleotides were prepared from 500 μM stocks. About 24 hours after cell seeding, 5 μL of ASO dissolved in PBS was added to the cell culture medium at a final concentration of 5 μM or 25 μM. The cells were incubated for 3 or 6 days without changing the medium. The cells incubated with ASO for 3 and 6 days were derived from different frozen stocks and had different passage numbers during the experiment.

[0572] After incubation, cells were harvested by removing the culture medium followed by cell lysis and RNA purification using the QIAGEN RNeasy 96 kit (cat 74181) according to the manufacturer's protocol. RNA was diluted 10-fold in water before the one-step qPCR reaction. For the one-step qPCR reaction, qPCR-mix (qScript from QuantaBio) was added. TM XLT One-Step RT-qPCR Low ROX, cat. no 95134-500) was mixed with two Taqman probes in a ratio of 10:1:1 (qPCR mixture: probe 1: probe 2) to generate a master mix. Taqman probes were purchased from Life Technologies: Mm00510952_m1, Mm00510954_m1, Mm01134666_m1 (Thermo Fisher Scientific, cat. 4351368, 4351368 and 4351370, respectively); GAPDH (cat. 4352339E) and ACTB (cat. 4352341E). Each experiment performed with Neuro2a cells included measurements of GAPDH and ACTB and one (Mm00510952_m1) or all three Tmem106b-specific probes, so that one Tmem106b and one control probe set were included in a given well. Then the premix (6 μL) and RNA (4 μL) were plated on a qPCR plate ( 384 wells, 4309849). After sealing, the plate was quickly spun at 1000g for 1 minute at room temperature and then transferred to a ViiaTM 7 system (Applied Biosystems, Thermo) and the following PCR conditions were used: 50°C for 15 minutes; 95°C for 3 minutes; 40 cycles: 95°C for 5 seconds, then lower the temperature at 1.6°C / sec, then 60°C for 45sec. Data were analyzed using QuantStudioTM Real_time PCR software. The results presented are normalized for different housekeeping genes. The results are shown in Table 9 below, as a control sample (PBS-treated cells), i.e., the lower the value, the greater the inhibitory effect. The results are also plotted in Figure 1 and Figure 2 Nearly all tested compounds (black dots) were found to inhibit target expression at 5 μM and 25 μM compared to the negative control gapmer (white dots), highlighting that TMEM106B is unexpectedly susceptible to oligonucleotide-directed inhibition.

[0573] Table 9: In vitro efficacy of oligonucleotides targeting TMEM106B mRNA in Neuro2a mouse cells. Experiments were performed in duplicate on day 3 (repeat A and B) and in a single experiment on day 6.

[0574]

[0575]

[0576]

[0577]

[0578] Example 2: Use of oligonucleotides to reduce TMEM106B in human SK-N-BE(2) cells in vitro

[0579] Oligonucleotides targeting TMEM106B were tested for their ability to reduce TMEM106B mRNA expression in human SK-N-BE (2) neuroblastoma cells obtained from ATCC (CRL-2271).

[0580] SK-N-BE(2) cells were grown in cell culture medium (MEM [Sigma, cat. no M2279] supplemented with 10% fetal bovine serum [Sigma, cat. no F7524], 1x GlutamaxTM [Sigma, cat. no 3050-038] 1x MEM non-essential amino acids solution [Sigma, cat. no M7145] and 0.025 mg / ml gentamicin [Sigma, cat. no G1397]. Cells were trypsinized every 5 days by washing with phosphate buffered saline (PBS) [Sigma cat. no 14190-094], then adding 0.25% trypsin-EDTA solution (Sigma, T3924), incubating at 37°C for 2-3 minutes and plating the cells after trituration. Cells were kept in culture for up to 15 passages.

[0581] For experimental purposes, 15,000 (day 3) or 25,000 (day 6) cells per well were seeded in 96-well plates (Nunc cat. no 167008) in 100 μL of growth medium. Oligonucleotides were prepared from 750 μM stocks. Approximately 24 hours after cell seeding, oligonucleotides dissolved in PBS were added to a final concentration of 5 μM or 25 μM. Cells were incubated for 3 or 6 days without changing the medium.

[0582] After incubation, remove the medium and add 125 μL 96 lysis buffer (Invitrogen 12173.001A) and 125 μL 70% ethanol were used to harvest the cells. RNA was purified according to the manufacturer's instructions and eluted in a final volume of 50 μL of water to obtain an RNA concentration of 10-20 ng / μl. Before the one-step qPCR reaction, the RNA was diluted 10 times in water. For the one-step qPCR reaction, qPCR-mix (qScriptTMXLE 1-step RT-qPCR from QuantaBio) was added. ROX, cat. no 95134-500) was mixed with two Taqman probes at a ratio of 10:1:1 (qPCR mixture: probe 1: probe 2) to generate a master mix. Taqman probes were purchased from Life Technologies: TMEM_Hs00998849_m1; GAPDH 4325792. The master mix (6 μL) and RNA (4 μL, 1-2 ng / μL) were then plated on a qPCR plate ( After sealing, the plate was quickly spun at 1000 g for 1 minute at room temperature and then transferred to a Viia™ 7 system (Applied Biosystems, Thermo) and the following PCR conditions were used: 50°C for 15 minutes; 95°C for 3 minutes; 40 cycles of 95°C for 5 seconds, then decreasing the temperature at 1.6°C / sec, then 60°C for 45sec.

[0583] Data were analyzed using QuantStudioTM Real-time PCR software. The results presented were normalized to GAPDH. The results are shown in Table 10 below as % of the control sample (PBS treated cells), i.e. the lower the value, the greater the inhibitory effect. The results are also plotted in Figure 4 and Figure 5 Compared to the negative control gapmer (white dots), almost all tested compounds (black dots) were found to inhibit target expression at 5 μM and 25 μM, highlighting that TMEM106B is unexpectedly susceptible to oligonucleotide-directed inhibition. Notably, compounds targeting the 3'UTR were found to be particularly effective, such as compounds 68_1, 73_1, 74_1, 79_1 and 82_1.

[0584] Table 10: In vitro efficacy of oligonucleotides targeting TMEM106B mRNA in SK-N-BE(2) human cells. Experiments were performed in duplicate (samples A and B)

[0585]

[0586]

[0587]

[0588]

[0589] Example 3: Cytotoxicity of Oligonucleotides

[0590] To measure whether LNA-modified oligonucleotides induce apoptosis, a caspase assay was applied as described herein.TM NIH 3T3 cells (ECACC cat. 93061524) were transfected with 100 nM or 30 nM LNA oligonucleotides at 2000, and the activation of caspase 3 and caspase 7 was measured 24 hours later according to the following protocol adapted from Dieckmann et al. (Molecular Therapy: Nucleic Acids Vol. March 10, 2018). The experiment was repeated twice with slightly different protocols. Each repeat was performed in two 96-well plates. In each repeat experiment, a total of four measurements were performed for each LNA oligonucleotide at a given transfection concentration.

[0591] For the first replicate, the mouse embryonic fibroblast cell line NIH 3T3 was grown in m3T3 medium (DMEM AQ (Sigma: D0819) supplemented with 10% FBS and 25 μg / ml gentamicin) at 37°C and 5% CO2. The cells were trypsinized and then seeded in 96-well plates (ViewPlate-96, PerkinElmer, cat 6005181) at a density of 4000 cells / well in 100 μl m3T3 medium and grown for 24 hours. LNA oligonucleotides were diluted with DPBS (Thermo Fisher Scientific, cat. 14190250) to a final concentration of 5 μM or 1.5 μM (a negative control with an oligonucleotide concentration of 0 μM was also included). Each diluted LNA oligonucleotide was mixed with Opti-MEM (Thermo Fisher Scientific cat. 31985047) at a ratio of 1 to 24 (volume), and 30 μl of LOM solution (Lipofectamine TM 2000 (Thermo Fisher Scientific cat.11668019), mixed with Opti-MEM (Thermo Fisher Scientific cat.31985047) in a ratio of 1 to 99 (volume), used immediately after preparation), and then incubated for 20 minutes. The medium was removed from the NIH 3T3 cell culture, and 50 μl of LNA oligonucleotides in LOM solution were added. Four hours later, 50 μl of m20F medium (800 ml of DMEM AQ (Sigma: D0819) mixed with 200 ml of FBS and 10 ml of 200 mM L-alanyl-L-glutamine and 500 μl of 50 mg / ml gentamicin) was added to each well. 24 hours after the LNA oligonucleotides were added to the cells, 100 μl Reagent (Promega, cat. G8093, prepared as specified by the manufacturer) was added to the cells, the plate was shaken at 500 rpm for 30 seconds and incubated at room temperature for 1 hour, then the back of the plate was sealed with BackSeal (PerkinElmer cat. 6005199) and luminescence was measured with EnSight Multimode Plate Reader (PerkinElmer cat. HH34000000).

[0592] For the second replicate, a similar protocol was followed with the following modifications: (1) the diluted LNA oligonucleotides were mixed with Opti-MEM in a ratio of 2 to 23 instead of 1 to 24; (2) 50 μl of Opti-MEM was added to the cells immediately before adding 50 μl of the mixture of LNA oligonucleotides with Opti-MEM and LOM solution to the cells; (3) instead of m20F, 50 μl of m30F (700 ml DMEM AQ (Sigma: D0819) mixed with 300 ml FBS and 10 ml 200 mM L-alanyl-L-glutamine and 500 μl 50 mg / ml gentamicin) was added; (4) before adding Immediately before adding reagents, 50 μl of culture medium was removed from the cells.

[0593] The luminescent signal measured by the EnSight microplate reader was divided by the average luminescent signal of the negative control wells in a given 96-well plate. The signals of different compounds at a given concentration were averaged across the plate and replicates (outliers were removed, which were defined as data points that were greater than or less than 1.5 interquartile ranges from the average signal in the replicates). The results are shown in Tables 11 and Figure 3 middle.

[0594] Table 11: Caspase activation in NIH 3T3 cells treated with oligonucleotides (repeated 4 times)

[0595]

[0596] Example 4: In vivo reduction of TMEM106B in mice

[0597] This example tests the ability of selected oligonucleotides from Example 1 to reduce TMEM106B in vivo in the mouse brain, as well as the acute and non-acute toxicity potential of the oligonucleotides.

[0598] C57BL / 6J male mice (23-32 g) were manually injected with 5 μl of 20 mg / ml saline-prepared LNA oligonucleotides into the right lateral cerebral ventricle under isoflurane anesthesia (0.3AP, 1.0ML, 3.0DV; six animals per group for TMEM106B-reactive compounds; 15 saline-treated animals; 15 animals treated with MAPT-reactive compounds, and 6 animals treated with negative control oligonucleotides).

[0599] After administration, acute reactions were classified into four levels: (1) normal behavior, (2) mild reaction (slight changes in activity / posture / gait within 30 min-1 hr), (3) moderate reaction (significant changes in activity / posture continued within 2-4 hrs), (4) severe (no activity, shallow breathing, moribund). The body weight of mice was measured immediately before and six days after administration of the oligonucleotides. A significant decrease in body weight is an indicator of potential non-acute toxicity. The results are shown in Table 13 below.

[0600] 7 days after injection, mice were killed with an overdose of isoflurane, then quickly decapitated, the brain was placed in an ice-cooled mouse brain slicer matrix (Stoelting), and cut into two (2 mm) coronal slices weighing about 30-40 mg (starting at 0.26 mm from the bregma). The tissue was immersed in RNALater solution (ThermoFisher Scientific, cat.AM7021) and stored at 4 ° C. RNA was isolated using the QIAcube robot workstation (Qiagen) using the RNeasy Mini kit (Qiagen, cat.74116). In short, brain fragments were transferred from RNALater solution to 1 mL RLT buffer in a 1.5 mL Eppendorf tube containing 3 mm tungsten carbide beads (Qiagen, cat 69997). Tissue was lysed (3 minutes at 30 Hz) using TissueLyser II (Qiagen) and centrifuged for 3 minutes at 20000 g. 550 μl of lysate (no foam, no precipitate) was transferred to a 2 mL Eppendorf tube and placed in a QIAcube pre-filled with all required reagents. RNA was purified according to the program "RNeasy Mini-Animal tissues and cells-Large samples (version 2)" and eluted with 50 μl H2O. RNA concentration was measured using a NanoDrop 8000 (ThermoFisher Scientific) spectrophotometer and adjusted to 2 ng / μl with H2O.

[0601] As described in Example 1, by using TMEM106B Mm00510952_m1 (Thermo Fisher Scientific, cat.4351370) as a probe and GAPDH probe (cat.4352339E, Thermo Fisher Scientific) for normalization, the expression level on the right hemisphere slice was basically measured. QuantStudioTM Real_time PCR software was used to analyze the data, and the readings of the technical repeat samples were averaged. The results are shown in Table 12 as a % of the average control sample (PBS-treated mice), that is, the lower the value, the greater the inhibitory effect.

[0602] Table 12: In vivo efficacy of oligonucleotides targeting TMEM106B.

[0603]

[0604]

[0605] Table 13: Acute responses and body weight changes observed in mice injected with oligonucleotides targeting TMEM106B.

[0606]

[0607] As can be seen from Tables 12 and 13, all oligonucleotides targeting TMEM106B are able to reduce TMEM106B mRNA after a single injection. Among the 10 oligonucleotides tested, one was found to cause severe acute toxicity. Only three animals were administered compound ID NO 161, which was euthanized immediately after severe reactions were observed, so the TMTM106B reduction of the compound was not measured. Some animals administered compound 144_1 showed obvious signs of weight loss, which may be due to the non-acute toxicity of the compound. Seven days after treatment, all the remaining oligonucleotide compounds seemed to be well tolerated.

[0608] Example 5: Treatment of mixed cultures of human iPSC neurons and astrocytes

[0609] In Example 2, human TMEM106b was first screened in human neuroblastoma cell lines. To evaluate the ability of these ASOs to reduce the target in human neurons, the efficacy of five human TMEM106b ASOs was evaluated in a cell culture mixture of human iPSC neurons and astrocytes: CMP ID 74_1, 65_1, 75_1, 71_1, 66_1.

[0610] Human iPSC-derived neural stem cells (MTI-GlobalStem, GSC-4311) were maintained in a 37°C CO2 cell culture incubator with NSC maintenance medium (DMEM / F12 (Genentech) / Neurobasal (ThermoFisher Scientific, 21103049), 1X GS22 (MTI-Global STEM, GSM-3200), 20ng / ml BDNF (Peprotech, 450-02), 20ng / ml FGF-basic (Peprotech, 100-18b), 20ng / ml EGF (Peprotech, AF-100-15), 0.5mM Glutamax (Gibco, 35050061), 0.11mM β-mercaptoethanol (Sigma-Aldrich CHECKCAT), 1X Normocin (InvivoGen, ant-nr-1), 50U / ml penicillin-streptomycin (ThermoFisher 15160122)) and the NSC maintenance medium was changed every 3-4 days until the cells were confluent. For neuronal differentiation, the cells were cultured at approximately 0.7 x 10 6 –1.0x10 6Cells were plated at a concentration of 10 cells / ml into T-650 cell culture flasks with 50 μg / ml PDL (Sigma-Aldrich, P6407) and 10 μg / ml recombinant human laminin (Sigma-Aldrich, St Louis, MO, USA). The cells were plated in neuronal differentiation medium (DMEM / F12 (Genentech) / Neurobasal (ThermoFisher Scientific 21103049), 1X GS21 (MTI-Global STEM GSM-3100), 1X N2 (MTI-GlobalStem GSM3300), 5μg / ml cholesterol (Sigma-Aldrich C3045), 1mM creatine (Sigma-Aldrich C0780), 100μM ascorbic acid (Sigma-Aldrich A8960), 0.5mM cAMP (Sigma-Aldrich D0627), 20ng / ml BDNF (Peprotech, 450-02), 20ng / ml GDNF (Peprotech, 450-10), 1μg / ml mouse laminin (Invitrogen, 23017-015), 0.5mM Glutamax (Gibco, 35050061), 1X Normocin (InvivoGen, ant-nr-1), 50U / ml penicillin-streptomycin (ThermoFisher, 15160122), supplemented with Y27632 (Tocris, 1254), SU9516 (Tocris, 2907) and Cumate (System Biosciences AM100A-1). The plated cells were differentiated for 1 week; half the volume of differentiation medium was replaced every 3-4 days. After differentiation, the cells were plated at approximately 2.5×10 5 -5.5x 10 5 The cells were plated at a concentration of 100 μg / mL in 384-well or 96-well PDL-laminin-coated plates in pre-warmed differentiation medium supplemented with Y27632 Rock inhibitor (Tocris, 1254) and 1X RevitaCell (Gibco, A2644501) and maintained for 1 week; half the volume of differentiation medium was replaced every 3-4 days.

[0611] Primary human astrocytes (Life Technologies, N7805100) were maintained in a 37°C CO2 cell culture incubator in astrocyte culture medium (DMEM high glucose (Genentech), 10% FBS (VWR, 89510-198), 1XN2 (MTI-GlobalStem GSM3300), 1X Normocin (InvivoGen, ant-nr-1), 50U / ml penicillin-streptomycin (ThermoFisher, 15160122)); the culture medium was changed every 3-4 days until the cells were confluent. Astrocytes were then cultured at approximately 3.0x10 4 -8.0x 10 4 Human iPSC neurons (described in the previous paragraph) were added to 384-well or 96-well plates at a concentration of cells / ml in BrainPhys maintenance medium (BrainPhys Basal (STEMCELL Technologies, 05790), 1X GS21 (MTI-Global STEM GSM-3100), 1X N2 (MTI-GlobalStem GSM3300), 5 μg / ml cholesterol (Sigma-Aldrich C3045), 1 mM creatine (Sigma-Aldrich C0780), 10 nM β-estradiol (Sigma-Aldrich E2758), 200 nM ascorbic acid (Sigma-Aldrich A8960), 1 mM cAMP (Sigma-Aldrich D0627), 20 ng / ml BDNF (Peprotech, 450-02), 20 ng / ml GDNF (Peprotech, 450-10), 1 μg / ml mouse laminin (Invitrogen, 23017-015), 0.5 mM Glutamax (Gibco, 35050061), 1X Normocin (InvivoGen, ant-nr-1), 50 U / ml penicillin-streptomycin (ThermoFisher, 15160122), 1 ng / ml TGFβ1 (Peprotech, 100-21); replace half the volume of BrainPhus maintenance medium every 3-4 days for 6-8 weeks.

[0612] For ASO treatment of human iPSC neurons, CMP ID 74_1, 65_1, 75_1, 71_1, 66_1 were diluted from the stock in the middle 96-well plate in a 9-point 3-fold serial dilution (10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.12 μM, 0.04 μM, 0.0137 μM, 0.0045 μM, 0.0015 μM) or a 5-point 10-fold serial dilution (10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM).

[0613] In a continuous 10-day incubation experiment, after 2 months of culture, ASO was added to the mixture of human iPSC neurons and astrocytes at the above ASO concentrations (5 points 10 times). On days 3 and 7, 50% of the culture medium was replaced to maintain optimal cell health (no additional ASO was added). Ten days after the start of ASO treatment, cells were harvested for Taqman analysis according to the manufacturer's instructions of the TaqMan Gene Expression Cells-to-Ct kit (ThermoFisher Scientific, AM1728). According to the manufacturer's instructions, human neuronal TMEM106b Taqman assays were performed using specific gene expression assay probes for human TMEM106b and POL2RB as housekeeping gene normalizers (assay IDs were Hs00998849_m1 and Hs00946293_m1, respectively). TMEM106b expression levels were normalized to the POL2RB housekeeping gene and relative expression was calculated relative to the medium control (100%) (i.e., lower numbers indicate higher TMEM106b reduction). IC50 analysis was performed using Graph PadPrism software using the software curve fitting option. The results are shown in Tables 14 and 15 and Fig. 7A and 7B The structural formulas of CMPIDs 74_1, 65_1, 75_1, 71_1, 66_1 are as follows: Figure 9-13 shown.

[0614] Table 14: Percent reduction of TMEM106b mRNA relative to saline in mixed cultures of human iPSC neurons and astrocytes after 10 days of continuous treatment with serial dilutions of ASOs (n=3).

[0615]

[0616] From the data, it can be seen that ASO showed high potency in the range of 7.6 nM to 128.7 nM (Table 14, Fig. 7A ). In addition, it can be seen that human neuronal TMEM106b mRNA is almost completely eliminated.

[0617] In addition, the ASOs were also evaluated in a 24-hour pulse experiment to assess whether short-term ASO treatment could have long-term effects. After 2 months of culture, five human TMEM106b ASOs CMP ID 74_1, 65_1, 75_1, 71_1, 66_1 were added to the human iPSC neuron and astrocyte mixture at the ASO concentrations indicated above (9 point 3-fold dilutions). ASO treatment lasted only 24 hours, and then the cells were washed 3X with neuronal culture medium. On days 3 and 7, 50% of the culture medium was replaced to maintain optimal cell health. After 10 days of ASO treatment, cells were harvested and TMEM106B mRNA was obtained using the Taqman assay described above. The results are shown in Tables 15 and Figure 7B middle.

[0618] Table 15: Percent reduction of TMEM106b mRNA relative to saline in mixed cultures of human iPSC neurons and astrocytes following pulse treatment with serial dilutions of ASOs for 24 hours (n=3).

[0619]

[0620]

[0621] These results showed that the IC50 ranged from 62.5 nM to 1 μM (Table 15, Figure 7B ), and after only 24 hours of incubation, all five 10 μM human TMEM106b ASOs could effectively and almost completely eliminate human TMEM106b mRNA, and had a long-term effect of at least 10 days similar to long-term incubation (Table 14, Fig. 7A ).

[0622] Further study whether ASO treatment of human iPSC neurons and astrocytes leads to a decrease in TMEM106b protein levels. In a continuous 10-day incubation experiment, after 2 months of culture, ASO was added to a mixture of human iPSC neurons and astrocytes at a final concentration of 10 μM. On the 3rd and 7th days, 50% of the culture medium was replaced to maintain optimal cell health (without adding additional ASO). Ten days after starting ASO treatment, cells were harvested for protein analysis using RIPA buffer (Pierce 89900) with protease inhibitors (Roche 11836153001). All lysates were subjected to BCA microprotein concentration analysis according to the manufacturer's instructions to measure total protein concentration (Thermo Fisher Scientific, 23235). Protein analysis was performed on a Peggy Sue automated western instrument (Protein Simple) using a Peggy Sue kit (SM-S001) according to the manufacturer's instructions. Equal amounts of total protein were loaded. The antibody for TMEM106b was from Bethyl (A303-439A), and GAPDH for housekeeping gene normalization was from Norvus (NB100-56875).

[0623] Figure 7C Automated western blot results are shown. In the left panel, neuronal lysates after 10 days of treatment with control and CMP ID 65_1 ASO 10 μM were loaded into the indicated lanes. The lanes were then probed with anti-TMEM106b antibodies. The right panel shows the same sample lanes probed with anti-GAPDH antibodies. It can be seen that CMP ID 65_1 was able to reduce human TMEM106b protein levels after 10 days of treatment.

[0624] Example 6: Time course of in vivo reduction of TMEM106b mRNA and protein in mice

[0625] This example tests the ability of selected mouse ASOs, also used in Example 4 above, to reduce mRNA and protein long term 1, 2, 4, 8 and 12 weeks after a single ICV injection.

[0626] The data generated in Example 4 regarding the reduction of mRNA 1 week after a single ICV injection were accepted in this Example. Additional data on the reduction of mRNA and protein were generated at 1, 2, 4, 8 and 12 weeks after a single ICV injection.

[0627] These experiments used C57BL / 6J males from the Jackson Laboratory, 3–6 months of age. Mice were housed on a regular light / dark cycle (14:10 h) with free access to food (LabDiet 5010) and water. All injections and tissue collections were performed during the light phase. All protocols for mouse experiments were approved by the Institutional Animal Care and Use Committee and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

[0628] The animals were anesthetized with isoflurane, the hair on the parietal region of the skull was shaved, and the skin was cleaned with an antimicrobial povidone sulfonate solution and 70% ethanol or Cloraprep solution. A midline skin incision was made between the occipital bone and the forehead to identify the bregma. 100 μg ASO in a volume of 5 μl (saline) was injected into the right lateral ventricle of the mouse (-0.5AP, 1.0ML, 3.0DV) at a rate of 1 μl / sec using a 26-gauge 10 μl Hamilton syringe. One minute after the injection, the needle was slowly withdrawn. The incision was closed with tissue glue and buprenorphine was given for up to 3 days to relieve pain caused by the surgery.

[0629] At 1 (for raw mRNA data from Example 4), 2, 4, 8, and 12 weeks after injection, mice were euthanized by decapitation under a constant flow of inhaled anesthetic (isofluorane). The brain was placed on an ice-cold brain matrix and the right hemisphere was cut into two 2 mm slices. One slice was immediately placed in RNALater (Ambion) and stored at 4°C for qPCR. The second 2 mm slice was weighed, immediately snap frozen in liquid nitrogen and stored at -80°C for protein analysis.

[0630] For qPCR, the tissue was then transferred to RLT Buffer (Qiagen) lysis reagent and lysed using TissueLyser (Qiagen). RNA was extracted using the RNeasy Mini QIAcube kit (cat. 74116) with a QIACUBE workstation. RNA concentration was checked on a Nanodrop (as RNA-40, blank H20) and each sample was then diluted with water to give a 2 ng / μl solution. RNA was heat denatured at 90°C for 40 seconds. qPCR analysis was performed using qScript TM XLT One-Step RT-qPCR on an Applied Biosystems ViiA7 thermal cycler Low ROX (QuantaBio, cat. 95134-02K) was used as a probe, TMEM106b (cat. 4351368, ThermoFisherScientific) was used as a probe, and GAPDH (cat. 4352339E, ThermoFisherScientific) probe was used for normalization. The results are shown in Table 16 and Fig. 8A middle.

[0631] Table 16: Long-term reduction of TMEM106b mRNA in vivo

[0632]

[0633]

[0634] From Table 16 and Fig. 8A It can be concluded that the reduction in TMEM106b mRNA for CMP ID NO: 152_1 and 155_1 was greatest between 1 and 4 weeks post-injection. TMEM106b mRNA in ASO-treated animals did not return to baseline 12 weeks post-injection (saline control animals) compared to saline controls (n=3-6 / group), and a 30-35% reduction in mRNA was detected for both CMP ID NO: 152_1 and 155_1 at 12 weeks post-injection (n=6-7 / group).

[0635] For Western blotting, the second quick frozen section was homogenized in 10 volumes of RIPA buffer with complete Roche protease inhibitor cocktail (Roche) and PhosStop (Roche) using TissueLyser (Qiagen, 30 cycles / s, 3 minutes). The samples were then rotated at 4°C for 20 minutes and then centrifuged at 14,000 rpm (Gs) at 4°C for 20 minutes. The supernatant was collected and stored at -80°C. The protein samples were diluted 1 / 5 in LDS loading buffer (4x, Invitrogen) with reducing agent (10x, Invitrogen) and heated for denaturation at 95°C for 5 minutes. The samples were then stored on ice and stored at -20°C. Equal volumes of samples were separated on a 10% Bis-Tris gel with 1x MOPS running buffer, transferred to a nitrocellulose membrane (iBlot2, ThermoFisher), and blocked in TBS-Tween at room temperature with 5% skim milk powder. Blots were probed with rabbit anti-TMEM106b (A303-439; Bethyl, 1:500) or β-tubulin in 5% BSA at 4°C overnight. Blots were washed with TBST and incubated with HRP-conjugated secondary antibodies for 2 hours at room temperature and then developed using Supersignal West Dura ECL (ThermoFisher) on a ChemiDoc (Bio-Rad). Blots were quantified using Image Lab 5.2 (BioRad) and each lane was normalized to β-tubulin and then to a control sample. The results are shown in Tables 17 and Figure 8B middle.

[0636] Table 17: Long-term reduction of TMEM106b protein in vivo

[0637]

[0638]

[0639] Similarly, as can be seen from Table 17 and Figure 8B It can be concluded that between 2-4 weeks after injection, TMEM106b protein was reduced by 40-50% at maximum. Compared to saline controls (n=2-6 / group), TMEM106b protein did not return to baseline within 12 weeks after injection, but decreased by 39% in CMP ID NO:152_1 treated animals (n=6-7 / group) and 14% in CMP ID NO:155_1 treated animals (n=5-7 / group).

Claims

1. A therapeutic single-stranded antisense oligonucleotide of 24 to 50 nucleotides in length, comprising a continuous nucleotide sequence and an additional nucleotide that is complementary to the continuous nucleotide sequence and forms a stem-loop (hairpin) structure by hybridizing with the continuous nucleotide sequence, wherein the continuous nucleotide sequence consists of a sequence of ATGTttatcaccaaAATT, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, wherein the target sequence is a nucleotide sequence of position 21084 to position 21101 of SEQ ID NO:1, a nucleotide sequence of position 1555 to position 1572 of SEQ ID NO:2, a nucleotide sequence of position 21340 to position 21357 of SEQ ID NO:3, or a nucleotide sequence of position 1385 to position 1402 of SEQ ID NO:4, or wherein the contiguous nucleotide sequence consists of a sequence of CTGAaatactaccaTATA, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence being the nucleotide sequence of position 21214 to position 21231 of SEQ ID NO:1, the nucleotide sequence of position 1685 to position 1702 of SEQ ID NO:2, the nucleotide sequence of position 21467 to position 21484 of SEQ ID NO:3, or the nucleotide sequence of position 1512 to position 1529 of SEQ ID NO:4, or wherein the contiguous nucleotide sequence consists of a sequence of CgaaattaatctcaaCCCA, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 22110 to position 22128 of SEQ ID NO:1, a nucleotide sequence of position 2581 to position 2599 of SEQ ID NO:2, or wherein the contiguous nucleotide sequence consists of a sequence of TTTAatcataccaATCT, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence being the nucleotide sequence of position 23806 to position 23822 of SEQ ID NO:1, the nucleotide sequence of position 4277 to position 4293 of SEQ ID NO:2, the nucleotide sequence of position 24430 to position 24446 of SEQ ID NO:3, or wherein the contiguous nucleotide sequence consists of a sequence of CTCAaataaattaatCTCT, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 24045 to position 24063 of SEQ ID NO:1, a nucleotide sequence of position 4516 to position 4534 of SEQ ID NO:2, or wherein the contiguous nucleotide sequence consists of a sequence of TTCTtatttcaaatCTCA, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 24060 to position 24077 of SEQ ID NO:1, a nucleotide sequence of position 4531 to position 4548 of SEQ ID NO:2, or wherein the contiguous nucleotide sequence consists of a sequence of TCTTatttcaaatCTCA, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 24060 to position 24076 of SEQ ID NO:1, a nucleotide sequence of position 4531 to position 4547 of SEQ ID NO:2, or wherein the contiguous nucleotide sequence consists of a sequence of TAACagtctttttACTC, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 24812 to position 24828 of SEQ ID NO:1, a nucleotide sequence of position 5283 to position 5299 of SEQ ID NO:2, a nucleotide sequence of position 25429 to position 25445 of SEQ ID NO:3, or wherein the contiguous nucleotide sequence consists of a sequence of ACTAtaacagtCTAC, and the therapeutic single-stranded antisense oligonucleotide is complementary to a target sequence, the target sequence is a nucleotide sequence of position 25392 to position 25406 of SEQ ID NO: 1, a nucleotide sequence of position 5863 to position 5877 of SEQ ID NO: 2, and wherein the capital letters in the single-stranded antisense oligonucleotide represent beta-D-oxy LNA nucleosides, the lowercase letters represent DNA nucleosides, all LNACs are 5-methylcytosine, and all internucleoside bonds are phosphorothioate internucleoside bonds. 2 . The single-stranded antisense oligonucleotide according to claim 1 , wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is ATGTttatcaccaaAATT.

3. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or its consecutive nucleotide sequence is CTGAaatactaccaTATA. 4 . The single-stranded antisense oligonucleotide according to claim 1 , wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is CgaaattaatctcaaCCCA.

5. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is TTTAatcataccaATCT. The single-stranded antisense oligonucleotide according to claim 1 , wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is CTCAaataaattaatCTCT.

7. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is TTCTtatttcaaatCTCA.

8. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is TCTTatttcaaatCTCA.

9. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is TAACagtctttttACTC.

10. The single-stranded antisense oligonucleotide according to claim 1, wherein the single-stranded antisense oligonucleotide or a consecutive nucleotide sequence thereof is ACTAtaacagtCTAC.

11. A conjugate comprising the single-stranded antisense oligonucleotide according to any one of claims 1 to 10, and at least one conjugate moiety covalently attached to the single-stranded antisense oligonucleotide.

12. A pharmaceutically acceptable salt of the single-stranded antisense oligonucleotide according to any one of claims 1 to 10 or the conjugate according to claim 11.

13. A pharmaceutical composition comprising the single-stranded antisense oligonucleotide according to any one of claims 1 to 10 or the conjugate according to claim 11 and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

14. A method for regulating TMEM106B expression in a target cell expressing TMEM106B in vitro, the method comprising administering to the cell an effective amount of the single-stranded antisense oligonucleotide of any one of claims 1 to 10, the conjugate of claim 11, the pharmaceutically acceptable salt of claim 12, or the pharmaceutical composition of claim 13.